1. Context {#sec138260}
==========

Breast cancer (BC) counts the most common cause of cancer related death among women. The studies reported about 235303 new cases of BC and about 40430 death records per year in the United States ([@A35099R1]). BC is the result of collaboration of many variables including environmental, reproductive, lifestyle, and genetic related factors ([@A35099R2]) and approximately 10% of BC cases are attributed to genetic factors ([@A35099R3]).

Mutations in high-penetrance genes such as BRCA1, BRCA2, TP53 and PTEN are demonstrated to contribute in BC susceptibility ([@A35099R4]). However, they are counted only for 25% of inherited BC risk ([@A35099R5]). A combined polymorphism effect of moderate and common low risk genes can clear remaining hereditary BC risk ([@A35099R6]). Base-excision repair (BER) genes are an important subcategory of DNA repair genes, which fix DNA base damage due to X-rays, oxygen radicals, and alkylating agents ([@A35099R7]). BER pathway excise oxidized DNA bases when oxidized DNA damage occur ([@A35099R8]). Mutations in BER genes by cumulative effect of endogenous and exogenous mutagens result in apoptosis or cell overgrowth and cancer. Known polymorphisms of DNA repair genes can be associated with the risk of many types of cancer such as lung ([@A35099R9]), colorectal ([@A35099R10]), bladder ([@A35099R11]), and BC ([@A35099R12]). On the other hand, there are evidences demonstrating no association or protective effect of BER genes with breast cancer ([@A35099R11], [@A35099R13], [@A35099R14]).

X-ray repair cross-complementing group 1 gene (XRCC1) and 8-oxoguanine DNA glycosylase (OGG1) play an important role in base-excision repair pathway. XRCC1 acts in BER encoding scaffolding protein that assemble together proteins of the DNA repair complex ([@A35099R15], [@A35099R16]). Arg194Trp, Arg280His and Arg399Gln amino acid substitution are the most common studied single nucleotide polymorphisms of XRCC1. OGG1 encodes a DNA glycosylase, an important enzyme in the repair of 8-oxoguanine ([@A35099R17]). Amino acid replacement of serine (Ser) with cysteine (Cys) at codon 326 (Ser326Cys, rs1052133) as a result of common C/G single nucleotide polymorphism (SNP) in exon 7 of hOGG1 gene is associated with decreased hOGG1 repair activity ([@A35099R18]).

There are studies recommending variation in association of genetic polymorphisms and diseases in different ethnicities and geographical populations ([@A35099R19], [@A35099R20]). There is no consensus among researchers regarding association between XRCC1 ([@A35099R21]-[@A35099R24]) and OGG1 ([@A35099R12], [@A35099R25], [@A35099R26]) with BC. A case-control study in the United States and Poland populations which evaluated association of BER genes with BC ([@A35099R27]) showed no association for XRCC1 and OGG1 in both populations. While other studies ([@A35099R28]) ([@A35099R29]) suggested association of XRCC1 (codon 194, codon 280, and codon 399) and OGG1 (codon 326) with breast cancer.

2. Objectives {#sec138261}
=============

As such, we aimed to conduct a comprehensive systematic review to address the association of XRCC1 and OGG1 polymorphisms with breast cancer.

3. Data Sources {#sec138262}
===============

The systematic review was conducted according to the meta-analysis of observational studies in epidemiology (MOOSE) group's criteria ([@A35099R30]). To extract all studies around genetic polymorphisms and breast cancer, we performed a sensitive search in PubMed, PubMed central and ISI web of knowledge from their commencements until September 2014. The search was carried out using keywords "Breast Neoplasms", "Breast Tumor", "Human Mammary Neoplasm", "Human Mammary Carcinoma", "Cancer of Breast, Breast Cancer", "Mammary Cancer", "Malignant Neoplasm of Breast", "Malignant Tumor of Breast", "Breast Carcinoma", "Cancer of the Breast", "Ductal Carcinoma of Breast", "Lobular Carcinoma of Breast", "Medullary Breast Cancer", "Breast Tumor" and "In Situ Breast Cancer" with Boolean "OR" between them combining "Polymorphism" with Boolean "AND" (each dataset detailed search string and retrieved results reported in Appendix 1). Search results were limited to human studies. We also performed contemporary hand search of reference lists of final retrieved studies, meta-analysis and systematic reviews.

4. Study Selection {#sec138263}
==================

All longitudinal cohorts (conventional cohort and historical cohort studies) and case-control studies (conventional case-control, case-cohort, nested case-control, matched case-control and unmatched case-control studies) investigating association of breast cancer with XRCC1 and OGG1 genes and their polymorphisms were eligible for initial inclusion. Also, all types (carcinomas, sarcomas) and grades (low, intermediate/moderate and high grade) of breast cancer were considered in this review. The criteria for exclusion of articles on the basis of title and abstract screening were: 1) Studies with no control group, 2) non-research articles (all type of letters, comments, and editorial), 3) animal studies, 4) case reports and case series studies, 5) considered occurrence of secondary/metastatic breast cancer or all-cause mortality as an outcome , 6) considered patients undergoing any type of intervention and 7) studies without breast cancer (pre/post-menopausal) as outcome. If the same population had been studied in two or more different studies (articles), we chose the most comprehensive and the most recent one.

5. Data Extraction {#sec138264}
==================

Two authors screened titles and abstracts and extracted all needed information from eligible studies after exclusion of duplicate titles. If there was a disagreement in each stage, three authors discussed conflicting results. EndNote X7 software was used to manage review and organize screening.

The following data were extracted from each study: name of first authors, date of publication, study design, source of controls, considered confounders in each models, genotyping methods, population ethnicity, total number of cases and controls, menopausal status of cases and controls, number of cases and controls according to genotypes and menopausal status, mean age of cases and controls, frequency of each genotypes separately and odds ratios for homozygote, heterozygote and combined model.

Because of the potential hazards of assessing the quality of studies using mechanical checklist and scoring the pre-considered item which is not made specifically for genetic epidemiology researches ([@A35099R31]-[@A35099R34]). For quality assessment procedure, we used four research methodological components causing bias for the association between gene polymorphisms and breast cancer risk, including source of controls sampling, population ethnicity, sample size of studies and menopausal status of cases and controls (Appendix 2 to 5). In order to minimize potential errors, considered data extracted on a former piloted Microsoft Excel worksheet, accompanied by predefined instructions for reviewers. In final stage, senior researcher re-checked extracted data. If clarifications and more information (or unavailable full texts) were needed, we contacted the first and corresponding author for additional data.

6. Results {#sec138270}
==========

6.1. Eligible Studies {#sec138265}
---------------------

A total of 2424 titles were identified in initial electronic search. After final screening, 45 eligible publications (including 49 studies) through primary search, 13 publications (14 studies) through hand search of references list of retrieved citations and 6 through an update search of databases were retrieved ([Figure 1](#fig26183){ref-type="fig"}). Two studies ([@A35099R35], [@A35099R36]) were excluded because of having overlapping population with two others ([@A35099R37], [@A35099R38]). Overall, 62 publications (67 studies) were included in this study according to inclusion and exclusion criteria ([@A35099R12], [@A35099R21]-[@A35099R23], [@A35099R25]-[@A35099R29])([@A35099R37]-[@A35099R89]). General characteristics of all eligible studies separated for each gene are provided in Appendix 6 to 9. Different ethnicities populations in the same study were considered as separated study populations (five publications comprised of two populations with different ethnicities) ([@A35099R27], [@A35099R43], [@A35099R47], [@A35099R68], [@A35099R83]). From these, 35 studies worked on Arg194Trp, 12 studies evaluated Arg280His, 56 assessed Arg399Gln, and 19 studies focused on Ser326Cys. All studies consist of retrospective confirmed breast cancer cases and cancer-free controls and were published during 2001 to 2015. Among retrieved studies, 17 also presented information on menopausal status and six studies were conducted on postmenopausal women. Considering geographical location, 24 studies were carried out in North America, 21 in Europe, 19 in Asia, 2 in Latin America and 2 in Africa. To have a better view of measure of association, ORs were recalculated for five studies which did not take wild type as reference category ([@A35099R46], [@A35099R52], [@A35099R56], [@A35099R74], [@A35099R87]), four studies because of stratification were based on family history of breast cancer ([@A35099R22], [@A35099R44], [@A35099R48], [@A35099R86]) and one because of stratification was based on recreational activity ([@A35099R63]).

![Flow Chart of the Reviewing Process for the Relationship Between Polymorphism and Breast Cancer](ijcp-09-01-3467-i001){#fig26183}

6.2. Arg194Trp {#sec138266}
--------------

General characteristics of eligible studies are exhibited in Appendix 6. The 35 studies on Arg194Trp consisted of 14,793 breast cancer cases and 15,409 controls. Sample size of the studies ranged from 74 to 2,833 individuals. The largest sample size belonged to Zhang's study ([@A35099R27]) and Sterpone's study had the lowest sample size ([@A35099R38]). Tryptophan (Trp) allele frequency ranged from 0.03 to 0.53 in cases and 0.02 to 0.57 in controls. Most of the studies (16 of 35) were conducted in the United States of America. Clinic (or hospital) based case-control studies were the most common design (19 of 35). In addition, polymerase chain reaction-restriction fragment length polymorphism method (PCR- RFLP) was the most used genotyping method (20 of 35).

Among these 35 researches, four studies ([@A35099R28], [@A35099R39], [@A35099R70], [@A35099R71])28, 39, 70, 71) showed significant association between Arg194Trp polymorphism and breast cancer comparing Trp carriers versus wild type and two ([@A35099R21], [@A35099R59]) showed marginally significant association. On the contrary, one study displayed protective effects ([@A35099R66]). ORs ranged from not calculable (NC) (not enough number of exposed individuals) to 8.74 (adjusted) and NC to 3.87 (unadjusted) for homozygote versus wild type, from 0.44 to 4.42 (adjusted) and 0.35 to 4.59 (unadjusted) for heterozygote versus wild type and from 0.62 to 4.28 (adjusted) and 0.35 to 4.571 (unadjusted) for Trp carriers versus wild type. After considering stratification for menopausal status, only one study ([@A35099R28]) reported significant association for post menopause and none showed association for premenopausal women. Oppositely, Patel ([@A35099R69]) showed protective effect of Arg194Trp polymorphism on postmenopausal women ([Table 1](#tbl35585){ref-type="table"}).

###### Adjusted and Unadjusted Odds Ratio of Studies Assessing the Association Between XRCC1 Arg194Trp Polymorphism and Breast Cancer

  References                                                           Menopausal Status   Trp/Trp Versus Arg/Arg^[a](#fn37873){ref-type="table-fn"}^   Arg/Trp Versus Arg/Arg^[a](#fn37873){ref-type="table-fn"}^   Trp/Trp and Arg/Trp Versus Arg/Arg^[a](#fn37873){ref-type="table-fn"}^                                                                                 
  -------------------------------------------------------------------- ------------------- ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------- -------------------- ---------------------------------------------------------
  **Duell E. J. (2001) (African-Americans) (**[@A35099R47]**)**        Mix                 \-                                                           NC^[b](#fn37874){ref-type="table-fn"}^                       \-                                                                       0.64 (0.28 - 1.42)^[b](#fn37874){ref-type="table-fn"}^   0.70 (0.30 - 1.50)   \-
  **Duell E. J. (2001) (White) (**[@A35099R47]**)**                    Mix                 \-                                                           NC^[b](#fn37874){ref-type="table-fn"}^                       \-                                                                       0.75 (0.40 - 1.39)^[b](#fn37874){ref-type="table-fn"}^   0.70 (0.40 - 1.30)   \-
  **Kim S. U. (2002) (**[@A35099R57]**)**                                                                                                                                                                                                                                                                                                                                   
                                                                       Mix                 0.90 (0.48 - 1.67)                                           \-                                                           1.10 (0.76 - 1.73)                                                       \-                                                       \-                   1.08 (0.71 - 1.62)^[b](#fn37874){ref-type="table-fn"}^
                                                                       Pre                 1.30 (0.57 - 2.95)                                           \-                                                           1.30 (0.74 - 2.18)                                                       \-                                                       \-                   1.27 (0.74 - 2.18)^[b](#fn37874){ref-type="table-fn"}^
                                                                       Post                0.50 (0.17 - 1.32)                                           \-                                                           1.00 (0.50 - 1.86)                                                       \-                                                       \-                   0.83 (0.42 - 1.62)^[b](#fn37874){ref-type="table-fn"}^
  **Han J. (2003) (**[@A35099R51]**)**                                 Mix                 \-                                                           1.33 (0.17 - 10.00)^[b](#fn37874){ref-type="table-fn"}^      \-                                                                       0.79 (0.61 - 1.03)^[b](#fn37874){ref-type="table-fn"}^   0.79 (0.60 - 1.04)   0.81 (0.62 - 1.05)
  **Moullan N. (2003) (**[@A35099R67]**)**                             Mix                 1.61 (0.10 - 26.10)                                          \-                                                           0.95 (0.56 - 1.61)                                                       \-                                                       \-                   1.02 (0.61 - 1.71)^[b](#fn37874){ref-type="table-fn"}^
  **Smith T. R. (2003) (84)**                                          Mix                 NC                                                           \-                                                           1.47 (0.80 - 2.70)                                                       \-                                                       1.60 (0.89 - 2.87)   \-
  **Smith T. R. (2003) (**[@A35099R22]**)**                            Mix                 \-                                                           NC^[b](#fn37874){ref-type="table-fn"}^                       \-                                                                       1.10 (0.58 - 2.02)^[b](#fn37874){ref-type="table-fn"}^   \-                   1.12 (0.60 - 2.03)^[b](#fn37874){ref-type="table-fn"}^
  **Deligezer U. (2004) (**[@A35099R45]**)**                           Mix                 \-                                                           NC                                                           \-                                                                       0.41 (0.16 - 1.06)                                       \-                   0.47 (0.19 - 1.17)
  **Forsti A. (2004) (**[@A35099R50]**)**                              Mix                 \-                                                           NC                                                           \-                                                                       1.27 (0.58 - 2.78)                                       \-                   \-
  **Chacko P. (2005) (**[@A35099R28]**)**                                                                                                                                                                                                                                                                                                                                   
                                                                       Mix                 2.78 (0.82 - 9.40)                                           2.73 (0.81 - 9.20)                                           1.89 (0.99 - 3.62)                                                       1.85 (1.01 - 3.38)                                       2.04 (1.12 - 3.72)   1.98 (1.13 - 3.48)
                                                                       Pre                 \-                                                           \-                                                           \-                                                                       \-                                                       1.35 (0.55 - 3.25)   \-
                                                                       Post                \-                                                           \-                                                           \-                                                                       \-                                                       2.75 (1.28 - 5.90)   \-
  **Patel A. V. (2005) (**[@A35099R69]**)**                            Post                \-                                                           \-                                                           \-                                                                       \-                                                       0.62 (0.40 - 0.95)   0.66 (0.45 - 0.97)
  **Shen J. (2005) (**[@A35099R81]**)**                                                                                                                                                                                                                                                                                                                                     
                                                                       Mix                 \-                                                           \-                                                           \-                                                                       \-                                                       0.93 (0.72 - 1.21)   \-
                                                                       Pre                 \-                                                           \-                                                           \-                                                                       \-                                                       0.78 (0.50 - 1.20)   \-
                                                                       Post                \-                                                           \-                                                           \-                                                                       \-                                                       1.00 (0.72 - 1.38)   \-
  **Brewster A. M. (2006) (**[@A35099R41]**)**                         Mix                 \-                                                           NC^[b](#fn37874){ref-type="table-fn"}^                       \-                                                                       1.69 (0.99 - 2.87)^[b](#fn37874){ref-type="table-fn"}^   1.20 (0.72 - 2.00)   1.12 (0.69 - 1.83)
  **Pachkowski B. F. (African-Americans) (2006) (**[@A35099R68]**)**   Mix                 0.70 (0.10 - 4.40)                                           \-                                                           1.00 (0.70 - 1.30)                                                       \-                                                       1.00 (0.70 - 1.30)   \-
  **Pachkowski B. F. (Whites) (2006) (**[@A35099R68]**)**              Mix                 0.90 (0.30 - 2.80)                                           \-                                                           0.90 (0.70 - 1.20)                                                       \-                                                       0.90 (0.70 - 1.20)   \-
  **Thyagarajan B. (2006) (**[@A35099R23]**)**                         Mix                 0.98 (0.21 - 4.63)                                           1.02 (0.23 - 4.57)                                           1.23 (0.21 - 4.63)                                                       1.20 (0.77 - 1.87)                                       1.21 (0.78 - 1.88)   1.18 (0.77 - 1.81)
  **Zhang Y. (2006) (**[@A35099R27]**)**                                                                                                                                                                                                                                                                                                                                    
                                                                       Mix                 0.50 (0.20 - 1.40)                                           \-                                                           0.90 (0.80 - 1.20)                                                       \-                                                       \-                   0.92 (0.73 - 1.15)^[b](#fn37874){ref-type="table-fn"}^
                                                                       Pre                 0.60 (0.00 - 10.30)                                          \-                                                           1.20 (0.80 - 1.80)                                                       \-                                                       \-                   1.19 (0.81 - 1.77)^[b](#fn37874){ref-type="table-fn"}^
                                                                       Post                0.50 (0.20 - 1.40)                                           \-                                                           0.80 (0.60 - 1.00)                                                       \-                                                       \-                   0.75 (0.55 - 1.02)^[b](#fn37874){ref-type="table-fn"}^
  **Silva S. N. (2007) (**[@A35099R21]**)**                                                                                                                                                                                                                                                                                                                                 
                                                                       Mix                 1.65 (0.10 - 27.43)                                          2.00 (0.12 - 32.14)                                          1.48 (0.95 - 2.32)                                                       1.46 (0.94 - 2.26)                                       1.49 (0.95 - 2.31)   1.47 (0.95 - 2.27)
                                                                       Pre                 NC                                                           0.05 (0.00 - 4.04)                                           0.78 (0.16 - 3.68)                                                       0.83 (0.18 - 3.69)                                       0.78 (0.16 - 3.68)   0.81 (0.18 - 3.63)
                                                                       Post                \-                                                           \-                                                           \-                                                                       \-                                                       \-                   \-
  **Loizidou M. A. (2008) (**[@A35099R60]**)**                         Mix                 \-                                                           0.95 (0.36 - 2.46)                                           \-                                                                       1.02 (0.82 - 1.28)                                       \-                   1.02 (0.81 - 1.28)^[b](#fn37874){ref-type="table-fn"}^
  **Mitra A. K. (2008) ([@A35099R66])**                                Mix                 \-                                                           0.41 (0.08 - 2.08)                                           \-                                                                       0.35 (0.18 - 0.65)                                       \-                   0.35 (0.19 - 0.64)
  **Sangrajrang S. (2008) (**[@A35099R29]**)**                                                                                                                                                                                                                                                                                                                              
                                                                       Mix                 0.70 (0.42 - 1.14)                                           0.75 (0.47 - 1.20)                                           1.08 (0.81 - 1.44)                                                       1.08 (0.82 - 1.41)                                                            1.01 ( 0.77 - 1.32)^[b](#fn37874){ref-type="table-fn"}^
                                                                       Pre                 0.88 (0.45 - 1.73)                                           \-                                                           1.23 (0.83 - 1.82)                                                       \-                                                       \-                   1.15 (0.80 - 1.65)^[b](#fn37874){ref-type="table-fn"}^
                                                                       Post                0.55 (0.26 - 1.16)                                           \-                                                           0.92 (0.60 - 1.42)                                                       \-                                                       \-                   0.85 (0.56 - 1.28)^[b](#fn37874){ref-type="table-fn"}^
  **Smith T. R. (Caucasian) (2008) (**[@A35099R83]**)**                Mix                 8.74 (0.97 - 78.23)                                          \-                                                           1.21 (0.74 - 1.97)                                                       \-                                                       \-                   1.34 (0.82 - 2.18)^[b](#fn37874){ref-type="table-fn"}^
  **Smith T. R. (African-American) (2008) (**[@A35099R83]**)**         Mix                 NC                                                           \-                                                           0.44 (0.12 - 1.67)                                                       \-                                                       \-                   0.82 (0.23 - 2.73)^[b](#fn37874){ref-type="table-fn"}^
  **Sobczuk A. (2009) (**[@A35099R37]**)**                             Post                \-                                                           0.71 (0.33 - 1.54)^[b](#fn37874){ref-type="table-fn"}^       \-                                                                       0.74 (0.36 - 1.50)^[b](#fn37874){ref-type="table-fn"}^   \-                   0.73 (0.37 - 1.41)^[b](#fn37874){ref-type="table-fn"}^
  **Ming-Shiean H. (2010) (**[@A35099R65]**)**                         Mix                 1.37 (0.87 - 2.17)                                           1.36 (0.88 - 2.14)                                           1.12 (0.84 - 1.47)                                                       1.09 (0.83 - 1.44)                                       1.20 (0.87 - 1.62)   1.17 (0.89 - 1.53)^[b](#fn37874){ref-type="table-fn"}^
  **Sterpone S. (2010) ([@A35099R38])**                                Mix                 \-                                                           NC                                                           \-                                                                       1.82 (0.43 - 7.66)                                       \-                   \-
  **Zipprich J. (2010) (**[@A35099R89]**)**                            Mix                 \-                                                           \-                                                           \-                                                                       \-                                                       1.17 (0.61 - 2.25)   \-
  **Liu L. (2011) (**[@A35099R59]**)**                                 Mix                 1.16 (0.84 - 1.59)                                           \-                                                           1.19 (0.99 - 1.44)                                                       \-                                                       1.19 (0.99 - 1.41)   \-
  **Al Mutairi F. M. (2013) (**[@A35099R39]**)**                       Mix                 \-                                                           NC                                                           \-                                                                       4.57 (1.47 - 14.21)                                      \-                   4.57 (1.47 - 14.21)
  **Przybylowska-Sygut K. (2013) (**[@A35099R70]**)**                  Mix                 \-                                                           NC                                                           \-                                                                       1.91 (1.15 - 3.14)                                       \-                   1.94 (1.15 - 3.32)^[b](#fn37874){ref-type="table-fn"}^
  **Ding P. (2014) (**[@A35099R46]**)**                                Mix                 \-                                                           0.99 (0.66 - 1.48)^[b](#fn37874){ref-type="table-fn"}^       \-                                                                       0.93 (0.73 - 1.18)^[b](#fn37874){ref-type="table-fn"}^   0.94 (0.75 - 1.18)   0.94 (0.74 - 1.18)^[b](#fn37874){ref-type="table-fn"}^
  **McCullough L. E. (2014) (**[@A35099R63]**)**                       Post                \-                                                           \-                                                           \-                                                                       \-                                                       \-                   0.91 (0.62 - 1.32)^[b](#fn37874){ref-type="table-fn"}^
  **Ramadan R. A. (2014) (**[@A35099R71]**)**                          Mix                 3.76 (1.07 - 13.17)                                          3.87 (1.24 - 12.05)                                          4.42 (2.08 - 9.41)                                                       4.59 (2.33 - 9.06)                                       4.28 (2.11 - 8.70)   4.45 (2.35 - 8.45)
  **Smolarz B. (2014) (**[@A35099R85]**)**                             Mix                 \-                                                           0.89 (0.34 - 2.28)                                           \-                                                                       0.59 (0.26 - 1.35)                                       \-                   0.68 (0.29 - 1.57)^[b](#fn37874){ref-type="table-fn"}^
  **Macias-Gomez, N. M. (2015) (**[@A35099R62]**)**                    Mix                 \-                                                           1.41 (0.64 - 3.14)                                           \-                                                                       1.01 (0.71 - 1.44)                                       \-                   1.06 (0.76 - 1.48)

Abbreviations: CI, confidence interval; NC, not calculable; OR, odds ratio.

^a^References category for calculation of odds ratio.

^b^ORs calculated by authors via Stata software (version 13).

6.3. Arg280His {#sec138267}
--------------

A total of 7,716 cases and 7,370 controls were studied for Arg280His. Zhang's study (27) had the largest sample size (n = 2,802) and Smith's study ([@A35099R83]) (this study consists of two different ethnic populations and here the African American population was studied) had the lowest (n = 128). Histidine (His) allele had the least frequency among studies population comparing to other three alleles. His allele frequency ranged from 0.03 to 0.11 in cases and from 0.03 to 0.14 in controls. Six of studies (4 publications) were conducted in the United States of America ([@A35099R27], [@A35099R68], [@A35099R83], [@A35099R89]). Seven studies (six publications) had a clinic-based design and five (four publications) had a population-based design. Genotyping of four studies ([@A35099R28], [@A35099R59], [@A35099R60], [@A35099R64]) was carried out by PCR-RFLP (Appendix 7).

Results of Arg280His showed significant association between Arg280His polymorphism and breast cancer comparing His carriers versus wild type only in one study ([@A35099R67]) with OR = 1.82 (1.06 - 3.15). ORs ranged from NC to 1.69 (adjusted) and NC to 4.68 (unadjusted) for homozygote versus wild type, from 0.55 to 1.80 (adjusted) and 0.56 to 1.13 (unadjusted) for heterozygote versus wild type and from 0.61 to 1.3 (adjusted) and 0.63 to 1.82 (unadjusted) for His carriers versus wild type. Stratification for menopausal status revealed marginally significant association in one study ([@A35099R29]) (OR = 1.71 (0.94 - 3.10); P = 0.07) and protective association of Arg280His polymorphism in another study ([@A35099R28]) (OR = 0.26 (0.1 - 0.66)) for post-menopausal women ([Table 2](#tbl35586){ref-type="table"}).

###### Adjusted and Unadjusted Odds Ratio of Studies Assessing the Association Between XRCC1 Arg280His Polymorphism and Breast Cancer

  References                                                           Menopausal Status   His/His Versus Arg/Arg ^[a](#fn37876){ref-type="table-fn"}^   Arg/His Versus Arg/Arg ^[a](#fn37876){ref-type="table-fn"}^   His/His and Arg/His Versus Arg/Arg ^[a](#fn37876){ref-type="table-fn"}^                                                                                  
  -------------------------------------------------------------------- ------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------- -------------------- ---------------------------------------------------------
  **Moullan N. (2003) (**[@A35099R67]**)**                             Mix                 NC                                                            \-                                                            1.80 (1.04 - 3.08)                                                        \-                                                        \-                   1.82 (1.06 - 3.15) ^[b](#fn37877){ref-type="table-fn"}^
  **Chacko P. (2005) (**[@A35099R28]**)**                                                                                                                                                                                                                                                                                                                                       
                                                                       Mix                 1.69 (0.29 - 9.63)                                            1.79 (0.32 - 10.05)                                           0.55 (0.29 - 1.03)                                                        0.56 (0.29 - 1.05)                                        0.61 (0.33 - 1.12)   0.63 (0.35 - 1.15)
                                                                       Pre                 \-                                                            \-                                                            \-                                                                        \-                                                        1.44 (0.62 - 3.70)   \-
                                                                       Post                \-                                                            \-                                                            \-                                                                        \-                                                        0.26 (0.10 - 0.66)   \-
  **Metsola K. (2005) (**[@A35099R64]**)**                             Mix                 \-                                                            NC ^[b](#fn37877){ref-type="table-fn"}^                       \-                                                                        1.13 (0.78 - 1.63) ^[b](#fn37877){ref-type="table-fn"}^   1.15 (0.80 - 1.66)   \-
  **Pachkowski B. F. (African-Americans) (2006) (**[@A35099R68]**)**   Mix                 1.10 (0.10 - 18.00)                                           \-                                                            1.30 (0.80 - 2.00)                                                        \-                                                        1.30 (0.80 - 1.90)   \-
  **Pachkowski B. F. (White) (2006) (**[@A35099R68]**)**               Mix                 NC                                                            \-                                                            1.20 (0.90 - 1.60)                                                        \-                                                        1.20 (0.90 - 1.60)   \-
  **Zhang Y. (2006) (**[@A35099R27]**)**                                                                                                                                                                                                                                                                                                                                        
                                                                       Mix                 1.00 (0.20 - 4.30)                                                                                                          1.10 (0.80 - 1.40)                                                                                                                                       1.10 (0.85 - 1.44) ^[b](#fn37877){ref-type="table-fn"}^
                                                                       Pre                 0.30 (0.00 - 3.50)                                            \-                                                            1.00 (0.60 - 1.40)                                                        \-                                                        \-                   0.94 (0.62 - 1.43) ^[b](#fn37877){ref-type="table-fn"}^
                                                                       Post                2.20 (0.20 - 21.20)                                           \-                                                            1.10 (0.80 - 1.60)                                                        \-                                                        \-                   1.14 (0.80 - 1.63) ^[b](#fn37877){ref-type="table-fn"}^
  **Loizidou M. A. (2008) (**[@A35099R60]**)**                         Mix                 \-                                                            4.68 (1.01 - 21.70)                                           \-                                                                        0.89 (0.71 - 1.11)                                        \-                   0.92 (0.73 - 1.15) ^[b](#fn37877){ref-type="table-fn"}^
  **Sangrajrang S. (2008) (**[@A35099R29]**)**                                                                                                                                                                                                                                                                                                                                  
                                                                       Mix                 \-                                                            \-                                                            \-                                                                        \-                                                        1.30 (0.88 - 1.93)   1.09 (0.76 - 1.58)
                                                                       Pre                 \-                                                            \-                                                            \-                                                                        \-                                                        0.99 (0.58 - 1.70)   \-
                                                                       Post                \-                                                            \-                                                            \-                                                                        \-                                                        1.71 (0.94 - 3.10)   \-
  **Smith T. R. (Caucasian) (2008) (**[@A35099R83]**)**                Mix                 NC                                                            \-                                                            0.72 (0.43 - 1.21)                                                        \-                                                        \-                   0.70 (0.40 - 1.19)^[b](#fn37877){ref-type="table-fn"}^
  **Smith T. R. (African-American) (2008) (**[@A35099R83]**)**         Mix                 NC                                                            \-                                                            0.66 (0.14 - 3.05)                                                        \-                                                        \-                   \-
  **Zipprich J. (2010) (**[@A35099R89]**)**                            Mix                 \-                                                            \-                                                            \-                                                                        \-                                                        0.87 (0.38 - 2.00)   \-
  **Liu L. (2011) (**[@A35099R59]**)**                                 Mix                 0.50 (0.21 - 1.18)                                            \-                                                            1.02 (0.81 - 1.28)                                                        \-                                                        0.98 (0.78 - 1.22)   \-

Abbreviations: CI, confidence interval; NC, not calculable; OR, odds ratio.

^a^References category for calculation of odds ratio.

^b^ORs calculated by authors via Stata software.

6.4. Arg399Gln {#sec138268}
--------------

Arg399Gln was the most popularly evaluated polymorphism and 27167 cases and 31998 controls were studied to estimate association between Arg399Gln polymorphism and breast cancer. The sample sizes ranged from 74 to 7,25 individuals in which the largest and smallest studies were carried out by Sapkota ([@A35099R79]) and Sterpone ([@A35099R38]), respectively. Glutamine (Gln) allele frequency ranged from 0.14 to 0.55 in cases and 0.11 to 0.57 in controls. 19 of 56 studies (16 publications) were conducted in the United States of America. Thirty-one studies used PCR-RFLP method for genotyping and thirty-three studies had clinic based study design (Appendix 8).

Among studies analyzing Arg399Gln, seven ([@A35099R28], [@A35099R38], [@A35099R47], [@A35099R61], [@A35099R71], [@A35099R80], [@A35099R86]) showed significant association between Arg399Gln polymorphism and breast cancer comparing Gln carriers versus wild type. Although six studies ([@A35099R27], [@A35099R29], [@A35099R53], [@A35099R62], [@A35099R64], [@A35099R66]) showed a borderline association, just one ([@A35099R64]) had P \< 0.05. Conversly, Zipprich et al. ([@A35099R89]) revealed protective effect of Arg399Gln on breast cancer risk (OR = 0.64 (0.41 - 1.00)). Calculated ORs ranged from 0.44 to 4.42 (adjusted) and 0.25 to 4.40 (unadjusted) for homozygote versus wild type, from 0.65 to 2.64 (adjusted) and 0.65 to 4.8 (unadjusted) for heterozygote versus wild type and from 0.64 to 2.89 (adjusted) and 0.60 to 4.66 (unadjusted) for Gln carriers versus wild type. Arg399Gln polymorphism showed to have an association with breast cancer in one study for Premenopausal women ([@A35099R28]) and three for postmenopausal woman ([@A35099R61], [@A35099R72], [@A35099R74]). Nonetheless, one study showed protective effect of Arg399Gln polymorphism for breast cancer risk ([@A35099R57]). Details of extracted ORs are reported in [Table 3](#tbl35587){ref-type="table"}.

###### Adjusted and Unadjusted Odds Ratio of Studies Assessing the Association Between XRCC1 Arg399Gln Polymorphism and Breast Cancer

  References                                                           Menopausal Status   Gln/Gln Versus Arg/Arg^[a](#fn37879){ref-type="table-fn"}^   Arg/Gln Versus Arg/Arg^[a](#fn37879){ref-type="table-fn"}^   Gln/Gln and Arg/Gln Versus Arg/Arg^[a](#fn37879){ref-type="table-fn"}^                                                                                  
  -------------------------------------------------------------------- ------------------- ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------- --------------------- ------------------------------------------------------------
  **Duell E. J. (African-Americans) (2001) (**[@A35099R47]**)**        Mix                 \-                                                           2.11 (0.52 - 9.99)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       1.54 (1.03 - 2.32)^[b](#fn37880){ref-type="table-fn"}^   1.70 (1.10 - 2.40)    \-
  **Duell E. J. (Whites) (2001) (**[@A35099R47]**)**                   Mix                 \-                                                           0.84 (0.52 - 1.33)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       1.12 (0.81 - 1.54)^[b](#fn37880){ref-type="table-fn"}^   1.00 (0.80 - 1.40)    \-
  **Kim S. U. (2002) (**[@A35099R57]**)**                              Mix                 2.40 (1.20 - 4.72)                                                                                                        0.80 (0.51--1.16)                                                                                                                                       0.96 (0.63 - 1.44)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Pre                 3.80 (1.44 - 10.30)                                                                                                       1.20 (0.72--2.10)                                                                                                                                       1.51 (0.87 - 2.60)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Post                1.40 (0.50 - 3.91)                                                                                                        0.40 (0.19--0.74)                                                                                                                                       0.50 (0.25 - 0.98)^[b](#fn37880){ref-type="table-fn"}^
  **Han J. (2003) (**[@A35099R51]**)**                                 Mix                 1.03 (0.77 - 1.37)                                           1.06 (0.81 - 1.39)                                           1.07 (0.88--1.30)                                                        1.06 (0.88 - 1.27)                                       \-                    1.04 (0.88 - 1.24)^[b](#fn37880){ref-type="table-fn"}^
  **Moullan N. (2003) (**[@A35099R67]**)**                             Mix                 1.00 (0.57 - 1.76)                                           \-                                                           0.96 (0.66--1.40)                                                        \-                                                       \-                    0.91 (0.64 - 1.29)^[b](#fn37880){ref-type="table-fn"}^
  **Shu X. O. (2003) (**[@A35099R82]**)**                              Mix                 1.20 (0.85 - 1.69)                                           1.22 (0.87 - 1.71)                                           0.90 (0.76--1.08)                                                        0.92 (0.77 - 1.09)                                                             1.00 (0.84 - 1.18)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Pre                 1.19 (0.78 - 1.80)                                           1.20 (0.79 - 1.81)                                           0.79 (0.63--0.98)                                                        0.79 (0.63 - 0.98)                                                             0.90 (0.73 - 1.10)^[b](#fn37880){ref-type="table-fn"}^
                                                                       post                1.13 (0.61 - 2.11)                                           1.19 (0.65 - 2.17)                                           1.19 (0.87--1.62)                                                        1.21 (0.90 - 1.64)                                                             1.20 (0.90 - 1.62)^[b](#fn37880){ref-type="table-fn"}^
  **Smith T. R. (2003) (**[@A35099R84]**)**                            Mix                 1.07 (0.58 - 1.96)                                           \-                                                           1.02 (0.70--1.51)                                                        \-                                                       1.03 (0.71 - 1.49)    \-
  **Smith T. R. (2003) (**[@A35099R22]**)**                            Mix                 \-                                                           1.09 (0.54 - 2.16)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       0.81 (0.53 - 1.25)^[b](#fn37880){ref-type="table-fn"}^   \-                    0.86 (0.57 - 1.29)^[b](#fn37880){ref-type="table-fn"}^
  **Deligezer U. (2004) (**[@A35099R45]**)**                           Mix                 \-                                                           1.26 (0.61 - 2.61)                                           \-                                                                       0.88 (0.53 - 1.47)                                       \-                    0.96 (0.59 - 1.56)
  **Figueiredo J. C. (2004) (**[@A35099R49]**)**                       Mix                 0.88 (0.57 - 1.37)                                           0.92 (0.60 - 1.41)                                           0.91 (0.67-1.23)                                                         0.92 (0.68 - 1.24)                                       \-                    0.92 (0.68 - 1.23)^[b](#fn37880){ref-type="table-fn"}^
  **Forsti A. (2004) (**[@A35099R50]**)**                              Mix                 \-                                                           0.89 (0.46 - 1.72)                                           \-                                                                       1.10 (0.75 - 1.61)                                       \-                    1.06 (0.73 - 1.52)^[b](#fn37880){ref-type="table-fn"}^
  **Huang C. S. (2004) (**[@A35099R52]**)**                            Mix                                                                              1.92 (0.79 - 4.69)^[b](#fn37880){ref-type="table-fn"}^                                                                                0.99 (0.61 - 1.60)^[b](#fn37880){ref-type="table-fn"}^                         1.11 (0.71 - 1.75)^[b](#fn37880){ref-type="table-fn"}^
  **Chacko P. (2005) (**[@A35099R28]**)**                              Mix                 2.69 (1.10 - 6.57)                                           2.66 (1.10 - 6.40)                                           2.04 (1.16-3.58)                                                         2.02 (1.16 - 3.49)                                       2.18 (1.30 - 3.66)    2.14 (1.29 - 3.58)
                                                                       Pre                                                                                                                                                                                                                                                                             6.32 (2.90 - 13.73)   
                                                                       Post                                                                                                                                                                                                                                                                            0.46 (0.36 - 1.57)    
  **Dufloth R. M. (2005) (**[@A35099R48]**)**                          Mix                 \-                                                           0.89 (0.26 - 2.85)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       0.84 (0.45 - 1.58)^[b](#fn37880){ref-type="table-fn"}^   \-                    0.85 (0.47 - 1.54)^[b](#fn37880){ref-type="table-fn"}^
  **Metsola K. (2005) (**[@A35099R64]**)**                             Mix                 1.39 (0.84 - 2.29)                                           \-                                                           1.24 (0.93--1.65)                                                        \-                                                       1.26 (0.96 - 1.66)    \-
  **Patel A. V. (2005) (**[@A35099R69]**)**                            Post                1.27 (0.79 - 2.02)                                           1.08 (0.71 - 1.63)                                           1.01 (0.73--1.39)                                                        0.95 (0.71 - 1.27)                                       1.06 (0.78 - 1.44)    0.98 (0.75 - 1.28)
  **Shen J. (2005) (**[@A35099R81]**)**                                Mix                 0.97 (0.73 - 1.29)                                                                                                        1.08 (0.90-1.29)                                                                                                                  1.06 (0.89 - 1.26)    
                                                                       Pre                 1.03 (0.62 - 1.70)                                                                                                        1.28 (0.93-1.75)                                                                                                                  1.23 (0.91 - 1.66)    
                                                                       Post                1.01 (0.71 - 1.44)                                                                                                        0.99 (0.79-1.24)                                                                                                                  0.99 (0.80 - 1.24)    
  **Brewster A. M. (2006) (**[@A35099R41]**)**                         Mix                 1.22 (0.73 - 2.06)                                           1.11 (0.67 - 1.83)                                           1.64 (1.00--2.69)                                                        1.48 (0.92 - 2.38)                                       \-                    1.24 (0.88 - 1.75)^[b](#fn37880){ref-type="table-fn"}^
  **Bu D. (2006) (**[@A35099R42]**)**                                  Mix                 \-                                                           1.10 (0.48 - 2.53)                                           \-                                                                       0.98 (0.58 - 1.65)                                       \-                    1.00 (0.58 - 1.69)^[b](#fn37880){ref-type="table-fn"}^
  **Pachkowski B. F. (African-Americans) (2006) (**[@A35099R68]**)**   Mix                 1.80 (0.80 - 3.80)                                           \-                                                           1.10 (0.90-1.50)                                                         \-                                                       1.20 (0.80 - 1.50)    \-
  **Pachkowski B. F. (Whites) (2006) (**[@A35099R68]**)**              Mix                 1.00 (0.80 - 1.30)                                           \-                                                           1.10 (0.90-1.30)                                                         \-                                                       1.10 (0.90 - 1.30)    \-
  **Thyagarajan B. (2006) (**[@A35099R23]**)**                         Mix                 0.91 (0.48 - 1.72)                                           0.91 (0.49 - 1.70)                                           1.29 (0.84--1.97)                                                        1.29 (0.85 - 1.95)                                       1.20 (0.80 - 1.79)    1.19 (0.80 - 1.77)
                                                                                                                                                                                                                                                                                                                                                                             
  **Zhai X. (2006) (**[@A35099R88]**)**                                Mix                 1.01 (0.60 - 1.70)                                                                                                        0.79 (0.57-1.08)                                                                                                                  0.82 (0.61 - 1.11)    
                                                                       Pre                                                                                                                                                                                                                                                                             0.83 (0.55 - 1.28)    
                                                                       Post                                                                                                                                                                                                                                                                            0.82 (0.54 - 1.25)    
  **Zhang Y. (USA) (2006) (**[@A35099R27]**)**                         Mix                 0.90 (0.80 - 1.10)                                                                                                        1.10 (0.90-1.20)                                                                                                                                        1.03 (0.92 - 1.15)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Pre                 0.80 (0.60 - 1.10)                                                                                                        1.00 (0.80-1.20)                                                                                                                                        0.92 (0.77 - 1.11)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Post                1.10 (0.80 - 1.30)                                                                                                        1.10 (0.90-1.30)                                                                                                                                        1.09 (0.95 - 1.26)^[b](#fn37880){ref-type="table-fn"}^
  **Zhang Y. (Poland) (2006) (**[@A35099R27]**)**                      Mix                 1.10 (0.90 - 1.40)                                                                                                        1.10 (1.00-1.30)                                                                                                                                        1.10 (0.97 - 1.25)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Pre                 1.00 (0.70 - 1.50)                                                                                                        1.20 (0.90-1.50)                                                                                                                                        1.12 (0.88 - 1.44)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Post                1.10 (0.80 - 1.30)                                                                                                        1.10 (0.90-1.30)                                                                                                                                        1.08 (0.92 - 1.25)^[b](#fn37880){ref-type="table-fn"}^
  **Costa S. (2007) (**[@A35099R44]**)**                               Mix                                                                              0.95 (0.57 - 1.53)^[b](#fn37880){ref-type="table-fn"}^                                                                                0.65 (0.47 - 0.90)^[b](#fn37880){ref-type="table-fn"}^                         1.64 (1.22 - 2.21)^[b](#fn37880){ref-type="table-fn"}^
  **Silva S. N. (2007) (**[@A35099R21]**)**                            Mix                 0.87 (0.50 - 1.49)                                           0.80 (0.47 - 1.36)                                           0.87 (0.62--1.22)                                                        0.83 (0.60 - 1.16)                                       0.87 (0.63 - 1.20)    0.83 (0.60 - 1.13)
                                                                       Pre                 0.52 (0.14 - 2.61)                                           0.65 (0.14 - 3.04)                                           0.49 (0.17--1.42)                                                        0.49 (0.17 - 1.35)                                       0.50 (0.18 - 1.32)    0.52 (0.20 - 1.32)
                                                                       Post                                                                                                                                                                                                                                                                                                  
  **Ali M. F. (2008) (**[@A35099R40]**)**                              Mix                 \-                                                           3.54 (0.69 - 10.65)^[b](#fn37880){ref-type="table-fn"}^      \-                                                                       1.52 (0.51 - 4.59)^[b](#fn37880){ref-type="table-fn"}^   \-                    2.05 (0.76 - 5.61)^[b](#fn37880){ref-type="table-fn"}^
  **Kipikasova L. (2008) (**[@A35099R58]**)**                          Mix                 \-                                                           0.95 (0.39 - 2.27)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       1.25 (0.68 - 2.29)^[b](#fn37880){ref-type="table-fn"}^   \-                    1.17 (0.67 - 2.04)^[b](#fn37880){ref-type="table-fn"}^
  **Loizidou M. A. (2008) (**[@A35099R60]**)**                         Mix                 \-                                                           0.90 (0.68 - 1.18)                                           \-                                                                       0.95 (0.80 - 1.14 )                                      \-                    0.94 (0.79 - 1.11)^[b](#fn37880){ref-type="table-fn"}^
  **Mitra A. K. (2008) (**[@A35099R66]**)**                            Mix                 \-                                                           2.91 (1.66 - 5.10)                                           \-                                                                       0.91 (0.56 - 1.50)                                       \-                    1.41 (0.90 - 2.19)
  **Saadat M. (2008) (**[@A35099R77]**)**                              Mix                 1.80 (0.90 - 3.61)                                           2.01 (1.02 - 3.94)                                           0.76 (0.47--1.20)                                                        0.76 (0.49 - 1.18)                                       0.93 (0.61 - 1.44)    0.95 (0.63 - 1.42)
                                                                       Pre                 1.93 (0.81 - 4.62)                                           1.87 (0.81 - 4.37)                                           0.88 (0.46--1.67)                                                        0.84 (0.45 - 1.56)                                       1.09 (0.61 - 1.96)    1.06 (0.60 - 1.85)
                                                                       Post                1.20 (0.23 - 6.07)                                           1.03 (0.21 - 5.05)                                           0.48 (0.18--1.31)                                                        0.46 (0.17 - 1.21)                                       0.57 (0.22 - 1.48)    0.53 (0.21 - 1.34)
  **Sangrajrang S. (2008) (**[@A35099R29]**)**                         Mix                 1.80 (0.99 - 3.29)                                           1.74 (0.99 - 3.10)                                           1.20 (0.90--1.60)                                                        1.17 (0.89 - 1.53)                                                             1.23 (0.94 - 1.61)^[b](#fn37880){ref-type="table-fn"}^1.09
                                                                       Pre                 1.45 (0.60 - 3.52)                                                                                                        1.05 (0.71--1.55)                                                                                                                                       (0.75 - 1.57)^[b](#fn37880){ref-type="table-fn"}^
                                                                       Post                1.84 (0.79 - 4.28)                                                                                                        1.30 (0.84--2.00)                                                                                                                                       1.40 (0.93 - 2.11)^[b](#fn37880){ref-type="table-fn"}^
  **Smith T. R. (Caucasian) (2008) (**[@A35099R83]**)**                Mix                 0.93 (0.56 - 1.54)                                           \-                                                           1.01 (0.74-1.40)                                                         \-                                                       1.00 (0.73 - 1.35)    1.03 (0.75 - 1.40)^[b](#fn37880){ref-type="table-fn"}^
  **Smith T. R. (African-American) (2008) (**[@A35099R83]**)**         Mix                 2.19 (0.09 - 52.25)                                          \-                                                           1.13 (0.44-2.91)                                                         \-                                                       1.18 (0.47 - 2.96)    1.33 (0.53 - 3.29)^[b](#fn37880){ref-type="table-fn"}^
  **Sobczuk A. (2009) (**[@A35099R37]**)**                             Post                \-                                                           0.89 (0.42 - 1.84)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       1.09 (0.54 - 2.18)^[b](#fn37880){ref-type="table-fn"}^   \-                    0.99 (0.52 - 1.88)^[b](#fn37880){ref-type="table-fn"}^
  **Syamala V. S. (2009) (**[@A35099R86]**)**                          Mix                 \-                                                           1.58 (0.99-2.52)^[b](#fn37880){ref-type="table-fn"}^         \-                                                                       1.60 (1.15 - 2.23)^[b](#fn37880){ref-type="table-fn"}^   \-                    1.59 (1.17 - 2.16)^[b](#fn37880){ref-type="table-fn"}^
  **Jakubowska A. (2010) (**[@A35099R54]**)**                          Mix                 0.67 (0.36 - 1.25)                                           0.67 (0.40 - 1.12)                                           0.73 (0.48-1.10)                                                         0.85 (0.60 - 1.19)                                                             0.80 (0.57 - 1.13)^[b](#fn37880){ref-type="table-fn"}^
  **Jelonek K. (2010) (**[@A35099R55]**)**                             Mix                 \-                                                           0.94 (0.43 - 1.93)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       0.72 (0.44 - 1.20)^[b](#fn37880){ref-type="table-fn"}^   \-                    0.77 (0.48 - 1.23)^[b](#fn37880){ref-type="table-fn"}^
  **Ming-Shiean H. (2010) (**[@A35099R65]**)**                         Mix                 1.31 (0.83 - 1.96)                                           1.26 (0.82 - 1.93)                                           1.05 (0.81--1.38)                                                        1.03 (0.78 - 1.36)                                       1.12 (0.87 - 1.42)    1.07 (0.82-1.40)^[b](#fn37880){ref-type="table-fn"}^
  **Romanowicz H. (2010) (**[@A35099R74]**)**                          Post                \-                                                           2.79 (1.51 - 5.21)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       1.29 (0.83 - 1.99)^[b](#fn37880){ref-type="table-fn"}^   \-                    1.59 (1.06 - 2.40)^[b](#fn37880){ref-type="table-fn"}^
  **Santos R. A. (2010) (**[@A35099R78]**)**                           Mix                 \-                                                           0.25 (0.04 - 1.30)                                           \-                                                                       0.73 (0.30 - 1.40)                                       \-                    0.60 (0.30 - 1.30)
  **Sterpone S. (2010) (**[@A35099R38]**)**                            Mix                 \-                                                           4.40 (1.13 - 17.08)                                          \-                                                                       4.80 (1.56 - 14.78)                                      \-                    4.66 (1.47 - 15.25)^[b](#fn37880){ref-type="table-fn"}^
  **Zipprich J. (2010) (**[@A35099R89]**)**                            Mix                 0.44 (0.18 - 1.11)                                           \-                                                           0.65 (0.39-1.10)                                                         \-                                                       0.64 (0.41 - 1.00)    \-
  **Liu L. (2001) (**[@A35099R59]**)**                                 Mix                 0.91 (0.66 - 1.27)                                           \-                                                           0.87 (0.72--1.05)                                                        \-                                                       0.88 (0.74 - 1.05)    \-
  **Roberts M. R. (2011) (**[@A35099R72]**)**                          Mix                                                                                                                                                                                                                                                                                                   
                                                                       Pre                 0.79 (0.44 - 1.42)                                                                                                        0.88 (0.62 -- 1.24)                                                                                                               0.86 (0.62 - 1.20)    
                                                                       Post                1.31 (0.94 - 1.83)                                                                                                        1.22 (0.99 -- 1.51)                                                                                                               1.24 (1.01 - 1.51)    
  **Hussien Y. M. (2012) (**[@A35099R53]**)**                          Mix                 1.60 (0.60 - 4.10)                                           \-                                                           1.70 (0.90 -- 3.10)                                                      \-                                                       1.70 (0.90 - 2.90)    \-
  **Al Mutairi F. M. (2013) (**[@A35099R39]**)**                       Mix                 \-                                                           1.25 (0.46 - 3.39)                                           \-                                                                       0.94 (0.51 - 1.72)                                       \-                    1.00 (0.57 - 1.75)
  **Przybylowska-Sygut K. (2013) (**[@A35099R70]**)**                  Mix                 \-                                                           0.86 (0.46 - 1.60)                                           \-                                                                       1.16 (0.76-1.78)                                         \-                    1.08 (0.70 - 1.65)^[b](#fn37880){ref-type="table-fn"}^
  **Sapkota Y. (2013) (**[@A35099R79]**)**                             Mix                 1.11 (0.94 - 1.31)                                           \-                                                           1.12 (1.00 - 1.25)                                                       \-                                                       \-                    \-
  **Ding P. (2014) (**[@A35099R46]**)**                                Mix                 \-                                                           2.69 (1.71 - 4.31)^[b](#fn37880){ref-type="table-fn"}^       \-                                                                       0.89 (0.70 - 1.14)^[b](#fn37880){ref-type="table-fn"}^   1.10 (0.88 - 1.37)    1.09 (0.87 - 1.38)^[b](#fn37880){ref-type="table-fn"}^
  **Luo H. (2014) (**[@A35099R61]**)**                                 Mix                 2.18 (1.06 - 4.50)                                                                                                        1.52 (1.01 - 2.31)                                                                                                                1.67 (1.12 - 2.47)    
                                                                       Pre                 0.77 (0.20 - 2.91)                                                                                                        1.53 (0.66-3.51)                                                                                                                  1.33 (0.60 - 2.91)    
                                                                       Post                2.57 (0.96 - 6.89)                                                                                                        1.84 (1.08-3.15)                                                                                                                  1.94 (1.16 - 3.24)    
  **McCullough L. E. (2014) (**[@A35099R63]**)**                       Post                \-                                                           \-                                                           \-                                                                       \-                                                       \-                    1.11 (0.87 - 1.42)^[b](#fn37880){ref-type="table-fn"}^
  **Ramadan R. A. (2014) (**[@A35099R71]**)**                          Mix                 4.42 (1.28 - 15.31)                                          3.56 (1.22 - 10.39)                                          2.64 (1.20 -- 5.08)                                                      2.62 (1.35 - 5.08)                                       2.89 (1.35 - 6.21)    2.77 (1.47 - 5.24)
  **Shadrina A. S. (2014) (**[@A35099R80]**)**                         Mix                 1.76 (1.21 - 2.57)                                           \-                                                           1.17 (0.92 -- 1.51)                                                      \-                                                       1.29 (1.02 - 1.63)    \-
  **Macias-Gomez (2015)N. M. (**[@A35099R62]**)**                      Mix                 \-                                                           2.71 (1.44 - 5.10)                                           \-                                                                       1.10 (0.80 - 1.51)                                       \-                    1.27 (0.94 - 1.72)

Abbreviations: CI, confidence interval; OR, odds ratio; USA, United States of America.

^a^References category for calculation of odds ratio.

^b^ORs calculated by authors via Stata software (version 13).

6.5. Ser326Cys {#sec138269}
--------------

A total of 9,417 cases and 11,087 controls were founded to be considered for Ser326Cys. Respectively, Roberts' study ([@A35099R72]) and Sterpone's ([@A35099R38]) study had the largest and smallest sample sizes of 2,941 and 74 individuals. Cysteine (Cys) allele was the most prevalent allele in this study and Cys frequency ranged from 0.21 to 0.63 in cases and 0.21 and 0.68 in controls. About half of studies of Ser326Cys polymorphism were conducted in Asia, particularly on Chinese populations. Design of 13 studies (12 publications) was clinic based (Appendix 9).

Among studies focusing on Ser326Cys, none showed significant association between Ser326Cys polymorphism and breast cancer comparing Cys carriers to wild type. Calculated ORs ranged from 0.69 to 1.70 (adjusted) and 0.22 to 1.46 (unadjusted) for homozygote versus wild type, from 0.82 to 1.20 (adjusted) and 0.33 to 1.37 (unadjusted) for heterozygote versus wild type and from 0.76 to 1.21 (adjusted) and 0.28 to 1.28 (unadjusted) for Cys carriers versus wild type. Stratification for menopausal status exhibited no significant association between Ser326Cys and breast cancer in pre and post-menopausal women, but Romanowicz-Makowska ([@A35099R75]) showed protective effect in post-menopausal women (OR = 0.49 (0.24 - 0.98)) ([Table 4](#tbl35588){ref-type="table"}).

###### Adjusted and Unadjusted Odds Ratio of Studies Assessing the Association Between OGG1 Ser326Cys Polymorphism and Breast Cancer

  First Author                                           Menopausal Status   Cys/Cys Versus Ser/Ser^[a](#fn37882){ref-type="table-fn"}^   Ser /Cys Versus Ser/Ser^[a](#fn37882){ref-type="table-fn"}^   Cys/Cys and Ser /Cys Versus Ser/Ser^[a](#fn37882){ref-type="table-fn"}^                                                                                                                     
  ------------------------------------------------------ ------------------- ------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  **Choi J. Y. (Korean) (2003) ([@A35099R43])**                                                                                                                                                                                                                                                                                                                                                     
                                                         Mix                 1.20 (0.71 - 2.00)                                           \-                                                            0.90 (0.59 - 1.53)                                                        \-                                                       \-                                                       0.94 (0.59 - 1.49)^[b](#fn37883){ref-type="table-fn"}^
                                                         Pre                 1.10 (0.57 - 2.22)                                           \-                                                            1.00 (0.56 - 1.93)                                                        \-                                                       \-                                                       1.03 (0.55 - 1.91)^[b](#fn37883){ref-type="table-fn"}^
                                                         Post                1.10 (0.46 - 2.45)                                           \-                                                            0.70 (0.34 - 1.63)                                                        \-                                                       \-                                                       0.77 (0.37 - 1.64)^[b](#fn37883){ref-type="table-fn"}^
  **Choi J. Y. (Japanese) (2003) (**[@A35099R43]**)**                                                                                                                                                                                                                                                                                                                                               
                                                         Mix                 1.70 (0.93 - 2.96)                                           \-                                                            1.20 (0.76 - 1.95)                                                        \-                                                       \-                                                       1.28 (0.81 - 2.02)^[b](#fn37883){ref-type="table-fn"}^
                                                         Pre                 1.90 (0.75 - 4.90)                                           \-                                                            1.30 (0.63 - 2.69)                                                        \-                                                       \-                                                       1.32 (0.65 - 2.66)^[b](#fn37883){ref-type="table-fn"}^
                                                         Post                1.30 (0.61 - 2.98)                                           \-                                                            1.20 (0.64 - 2.42)                                                        \-                                                       \-                                                       1.23 (0.65 - 2.34)^[b](#fn37883){ref-type="table-fn"}^
  **Vogel U. (2003) (**[@A35099R26]**)**                 Post                \-                                                           0.98 (0.52 - 1.86)                                            \-                                                                        0.84 (0.64 - 1.10)                                       \-                                                       0.85 (0.64 - 1.13)^[b](#fn37883){ref-type="table-fn"}^
  **Huang C. S. (2004) (52)**                            Mix                 \-                                                           0.82 (0.42 - 1.61)^[b](#fn37883){ref-type="table-fn"}^        \-                                                                        0.90 (0.48 - 1.71)^[b](#fn37883){ref-type="table-fn"}^   \-                                                       0.86 (0.48 - 1.58)^[b](#fn37883){ref-type="table-fn"}^
  **Cai Q. (2006) (**[@A35099R25]**)**                                                                                                                                                                                                                                                                                                                                                              
                                                         Mix                 1.06 (0.83 - 1.35)                                           \-                                                            1.17 (0.93 - 1.47)                                                        \-                                                       \-                                                       1.10 (0.88 - 1.38)^[b](#fn37883){ref-type="table-fn"}^
                                                         Pre                 0.99 (0.74 - 1.34)                                           \-                                                            1.08 (0.81 - 1.43)                                                        \-                                                       \-                                                       1.04 (0.79 - 1.37)^[b](#fn37883){ref-type="table-fn"}^
                                                         Post                1.18 (0.77 - 1.81)                                           \-                                                            1.37 (0.91 - 2.07)                                                        \-                                                       \-                                                       1.26 (0.84 - 1.88)^[b](#fn37883){ref-type="table-fn"}^
  **Rossner P., Jr. (2006) (**[@A35099R76]**)**          Mix                 1.01 (0.68 - 1.52)                                           0.99 (0.66 - 1.47)                                            1.06 (0.88 - 1.28)                                                        1.04 (0.87 - 1.24)                                       \-                                                       1.02 (0.86 - 1.22)^[b](#fn37883){ref-type="table-fn"}^
  **Zhang Y. (2006) (**[@A35099R27]**)**                                                                                                                                                                                                                                                                                                                                                            
                                                         Mix                 1.00 (0.70 - 1.40)                                           \-                                                            1.00 (0.80 - 1.20)                                                        \-                                                       \-                                                       0.98 (0.83 - 1.14)^[b](#fn37883){ref-type="table-fn"}^
                                                         Pre                 0.90 (0.50 - 1.50)                                           \-                                                            1.10 (0.80 - 1.40)                                                        \-                                                       \-                                                       1.02 (0.78 - 1.32)^[b](#fn37883){ref-type="table-fn"}^
                                                         Post                1.20 (0.70 - 1.90)                                           \-                                                            1.00 (0.80 - 1.20)                                                        \-                                                       \-                                                       1.01 (0.82 - 1.25)^[b](#fn37883){ref-type="table-fn"}^
  **Romanowicz-Makowska H. (2008) (**[@A35099R75]**)**   Post                \-                                                           0.62 (0.28 - 1.38)^[b](#fn37883){ref-type="table-fn"}^        \-                                                                        0.40 (0.18 - 0.87)^[b](#fn37883){ref-type="table-fn"}^   \-                                                       0.49 (0.24 - 0.98)^[b](#fn37883){ref-type="table-fn"}^
  **Sangrajrang S. (2008) (**[@A35099R29]**)**                                                                                                                                                                                                                                                                                                                                                      
                                                         Mix                 1.42 (0.97 - 2.09)                                           1.46 (1.02 - 2.10)                                            0.95 (0.67 - 1.34)                                                        0.99 (0.72 - 1.37)                                       \-                                                       1.14 (0.83 - 1.56)^[b](#fn37883){ref-type="table-fn"}^
                                                         Pre                 1.13 (0.67 - 1.91)                                           \-                                                            0.92 (0.58 - 1.48)                                                        \-                                                       \-                                                       1.12 (0.72 - 1.73)^[b](#fn37883){ref-type="table-fn"}^
                                                         Post                2.05 (1.14 - 3.69)                                           \-                                                            0.97 (0.58 - 1.61)                                                        \-                                                       \-                                                       1.17 (0.72 - 1.89)^[b](#fn37883){ref-type="table-fn"}^
  **Synowiec E. (2008) (**[@A35099R87]**)**              Mix                 \-                                                           0.22 (0.04 - 1.04)^[b](#fn37883){ref-type="table-fn"}^        \-                                                                        0.33 (0.06 - 1.40)^[b](#fn37883){ref-type="table-fn"}^   \-                                                       0.28 (0.05 - 1.10)^[b](#fn37883){ref-type="table-fn"}^
  **Ming-Shiean (2010)H. (**[@A35099R65]**)**            Mix                 1.09 (0.74 - 1.59)                                           1.09 (0.74 - 1.63)                                            0.97 (0.66 - 1.42)                                                        0.99 (0.67 - 1.47)                                       1.04 (0.80 - 1.46)                                       1.02 (0.71 - 1.48)^[b](#fn37883){ref-type="table-fn"}^
  **Sterpone S. (2010) (**[@A35099R38]**)**              Mix                 \-                                                           0.83 (0.10 - 6.65)                                            \-                                                                        1.37 (0.53 - 3.56)                                       \-                                                       1.03 (0.46 - 3.64)^[b](#fn37883){ref-type="table-fn"}^
  **Roberts M. (2011)R. (**[@A35099R72]**)**                                                                                                                                                                                                                                                                                                                                                        
                                                         Mix                 \-                                                           \-                                                            \-                                                                        \-                                                       \-                                                       \-
                                                         Pre                 1.17 (0.53 - 2.54)                                           \-                                                            1.00 (0.72 - 1.38)                                                        \-                                                       1.01 (0.74 - 1.38)                                       \-
                                                         Post                1.19 (0.77 - 1.85)                                           \-                                                            0.97 (0.79 - 1.19)                                                        \-                                                       0.99 (0.82 - 1.21)                                       \-
  **Kim K. Y. (2013) (**[@A35099R57]**)**                Mix                 \-                                                           0.83 (0.53 - 1.30)^[b](#fn37883){ref-type="table-fn"}^        \-                                                                        0.95 (0.66 - 1.38)^[b](#fn37883){ref-type="table-fn"}^   0.90 (0.64 - 1.27)                                       0.91 (0.64 - 1.30)^[b](#fn37883){ref-type="table-fn"}^
  **Xie H. (2013) (**[@A35099R12]**)**                                                                                                                                                                                                                                                                                                                                                              
                                                         Mix                 \-                                                           1.34 (0.97 - 1.84)                                            \-                                                                        1.10 (0.82 - 1.49)                                       \-                                                       1.19 (0.88 - 1.60)^[b](#fn37883){ref-type="table-fn"}^
                                                         Pre                 \-                                                           1.87 (1.14 - 3.06)                                            \-                                                                        1.08 (0.68 - 1.72)                                       \-                                                       1.34 (0.84 - 2.15)^[b](#fn37883){ref-type="table-fn"}^
                                                         Post                \-                                                           1.18 (0.73 - 1.89)                                            \-                                                                        1.02 (0.66 - 1.57)                                       \-                                                       1.07 (0.69 - 1.65)^[b](#fn37883){ref-type="table-fn"}^
  **Luo H. (2014) (**[@A35099R61]**)**                                                                                                                                                                                                                                                                                                                                                              
                                                         Mix                 0.69 (0.40 - 1.19)                                           \-                                                            0.82 (0.48 - 1.38)                                                        \-                                                       0.76 (0.46 - 1.24)                                       \-
                                                         Pre                 0.41 (0.14 - 1.18)                                           \-                                                            0.58 (0.21 - 1.64)                                                        \-                                                       0.49 (0.19 - 1.27)                                       \-
                                                         Post                0.83 (0.40 - 1.70)                                           \-                                                            1.01 (0.51 - 1.99)                                                        \-                                                       0.93 (0.49 - 1.76)                                       \-
  **McCullough L. E. (2014) (**[@A35099R63]**)**         Post                \-                                                           \-                                                            \-                                                                        \-                                                       \-                                                       0.98 (0.77 - 1.25)^[b](#fn37883){ref-type="table-fn"}^
  **Rodrigues P. (2014) (**[@A35099R73]**)**             Mix                 \-                                                           \-                                                            \-                                                                        \-                                                       1.82 (1.31 - 2.52)^[c](#fn37884){ref-type="table-fn"}^   \-
  **Smolarz B. (2014) (**[@A35099R85]**)**               Mix                 \-                                                           0.93 (0.34 - 2.51)                                            \-                                                                        1.02 (0.45 - 2.34)                                       \-                                                       1.00 (0.42 - 2.37)^[b](#fn37883){ref-type="table-fn"}^

Abbreviations: CI, confidence interval; OR, odds ratio.

^a^References category for calculation of odds ratio.

^b^ORs calculated by authors via Stata software (version 13).

^c^Cys/Cys versus Ser /Cys and Ser/Ser; Cys/Cys as reference category.

As part of a systematic review to address variations seen in the association between polymorphic genes involved in base excision repair pathway and risk of breast cancer, we identified all studies indexed in PubMed and Web of Sciences in which the risk of barest cancer for carriers of susceptibility alleles of XRCC1 and OGG1 genes were investigated. Collectively, there were 62 studies assessing the BER gene polymorphism in different population providing a wealth of information to look at the cause of variation in allele frequency as well as the magnitude of association between this polymorphic genes and breast cancer.

Etiology of breast cancer is characterized with major influence of endogenic estrogen exposure and gens involved in cancer susceptibility or genes involved in different pathways of estrogen metabolism ([@A35099R90]). The lifestyle and environmental factors play important role in modifying the magnitude of estrogen exposure in a background of several susceptibility genes ([@A35099R91]). The highly penetrate genes of BRCA1 and BRCA2 accounts for up to 25% of inherited breast cancer (where not more than 10% of breast cancer are considered as familial and inherited) ([@A35099R92], [@A35099R93]). The involvement of low-penetrate susceptibility polymorphic genes involved in the pathophysiologic pathways of breast tumor genesis play major role in sporadic breast cancer ([@A35099R94]). The polymorphic genes can be involved in several cellular mechanisms especially estrogen metabolism pathways, detoxification of xenobiotic, cell adhesion, and DNA damage and repair signaling. While polymorphic genes involved in estrogen metabolism are very specific to breast cancer susceptibility, polymorphic genes involved in DNA repair and damage play an important role in the etiology of many cancers including breast ([@A35099R95]). Among the many polymorphic genes involved in the etiology of breast cancer, Base excision repair polymorphic genes shows especially important role as a mechanism involved in repairing endogenous driven DNA damage, which may originate from wide range of normal metabolism. The magnitude of association (expressed as odds ratio in case-control and rate ration in cohort studies) between low penetrance genes and risk of cancer is very small and barely ranges more than 1.5. From population standpoint, the small magnitude of association seen between the susceptibility allele and risk of cancer is aggregated into an important causal factor in the light of high prevalence of susceptibility allele. As the systematic review result, the prevalence of susceptibility allele in controls group for XCCR1 Arg194Trp ranged from 2% in populations of Finland ([@A35099R50]) and Saudi Arabia ([@A35099R39]) to 57% in the population of Poland ([@A35099R37]). For XRCC1 Arg280His the prevalence ranged between 3% in African-American population of USA ([@A35099R68]) to 14% in population of India ([@A35099R28]). For XRCC1 Arg399Gln, the prevalence ranged between 11% for African-American population of the US ([@A35099R83]) to 57% for the population of Poland ([@A35099R37]). For OGG1 Ser326Cys, the prevalence ranged between 21% for populations of Spain ([@A35099R73]) and USA ([@A35099R27]) to 68% for the population of Poland ([@A35099R87]). The distribution of a susceptibility allele in a population is supposed to follow the Hardy-Weinberg law, unless a known population stratification or funder effect disturbs the HWE law ([@A35099R96]). In studies of association between a susceptible allele and risk of cancer when there is no indication of population stratification or funder effect, the differential frequency of the susceptibility allele among the diseased compared to non-diseased provides the bases for association studies. Lack of HWE law in distribution of susceptible allele confounds any study assessing association between susceptibility allele and cancer risk ([@A35099R97], [@A35099R98]). In our systematic review, it was observed that HWE law was assessed for all the studies.

In association studies of susceptibility allele and risk of breast cancer, controlling other risk factors such as risk factors related to life style and hormonal play an important role. Many studies reviewed in this systematic review included control for known risk factors; in some studies, the analysis were done based on subgroup analysis and some studies used statistical modeling. Studies included in our analysis control extraneous risk factors either through subgroup analysis (grouping the study subjects into pre and post menopause) or by using multivariable models. Many of the studies were case-control studies some of which were population and clinical based studies. As population based case and controls are less prone to bias, our systematic review identifies many studies whose results can be used for further studies such as met-analysis.

In epidemiology, systematic reviews are done for different purposes. Our systematic review's aim was to identify all studies that assessed the relationship between risk of breast cancer and susceptibility alleles of main base excision repair genes (XRCC1 and OGG1). The systematic approach makes sure that all studies are included and properly evaluated. The fact that our systematic review was able to use major databases (PubMed and Web of Sciences) indicates that we were able to identify all studies indexed in these two databases which cover a large part of English language indexed publications. The inclusion of two databases and manual search of the references of other systematic reviews and meta analyses have lower chances of missing major and important studies indicating high degrees of completeness.

The measure of association was another factor, which may be different among different populations. The difference depends on the frequency and magnitude of other modifying factors effecting and interacting with the BER genes. Our systematic review reveals that, the association between risk of breast cancer and XCRR1 and OGG1 susceptible allele depended on the model of inheritance and different model can show different effects on different population. Further studies are needed to assess the effect(s) of inheritance model on the risk of breast cancer.

7. Conclusions {#sec138271}
==============

Systematic search of major databases identify many studies addressing the relationship between breast cancer and susceptible alleles in the base excision repair genes and the fact that there are many variations in the magnitude of association depending on model of inheritance and the population of the study.
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The initial sensitive electronic search was performed from database commencement to 04 Sept 2014. The search updated in 22 April 2015. The details of strategy are shown in Appendix A1 (below table).

###### Details of Electronic Search Strategy ^[a](#fn37885){ref-type="table-fn"}^

  Database                                 Search Strategy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        N
  ---------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------
  **PubMed/NLM**                           ("Polymorphism") AND ("Breast Neoplasms" OR "Breast Tumor" OR "Human Mammary Neoplasm" OR "Human Mammary Carcinoma" OR "Cancer of Breast" OR "Breast cancer" OR "Mammary Cancer" OR "Malignant Neoplasm of Breast" OR "Malignant Tumor of Breast" OR "Breast Carcinoma" OR "Cancer of the Breast" OR "Ductal carcinoma of breast" OR "Lobular Carcinoma of breast" OR "Medullary breast cancer" OR "Breast tumor" OR "In Situ breast cancer")                                                                          5345
  **PMC/NLM**                              ("Polymorphism"\[ti\]) AND ("Breast Neoplasms" \[ti\] OR "Breast Tumor" \[ti\] OR "Human Mammary Carcinoma" \[ti\] OR "Cancer of Breast"\[ti\] OR "Breast cancer"\[ti\] OR "Mammary Cancer"\[ti\] OR "Malignant Neoplasm of Breast"\[ti\] OR "Malignant Tumor of Breast"\[ti\] OR "Breast Carcinoma"\[ti\] OR "Cancer of the Breast"\[ti\] OR "Ductal carcinoma of breast"\[ti\] OR "Lobular Carcinoma of breast"\[ti\] OR "Medullary breast cancer"\[ti\] OR "Breast tumor"\[ti\] OR "In Situ breast cancer"\[ti\])   138
  **ISI Web of Science/Thomson Reuters**   (Polymorphism ^[a](#fn37885){ref-type="table-fn"}^ breast cancer) Refined by: LANGUAGES: ( ENGLISH ) AND Databases: ( WOS ) AND RESEARCH AREAS: ( ONCOLOGY OR GENETICS HEREDITY OR BIOCHEMISTRY MOLECULAR BIOLOGY OR GERIATRICS GERONTOLOGY ) AND DOCUMENT TYPES: ( ARTICLE OR REVIEW OR CORRECTION ) Timespan: All years.                                                                                                                                                                                             1501

^a^ Calculated OR for different strata, but data not shown.

###### Quality of Studies Assessing the Association Between Ser326Cys Polymorphism and Breast Cancer ^[a](#fn37886){ref-type="table-fn"},[b](#fn37887){ref-type="table-fn"}^

  Study (year)                     Source of Control   Population Ethnicity   Sample Size   Menopausal Status   HWE Reported
  -------------------------------- ------------------- ---------------------- ------------- ------------------- --------------
  **Choi (2003)**                  \+                  \+                     \+            \+                  \+
  **Vogel (2003)**                 \+                  \-                     \+            \+                  \+
  **Huang (2004)**                 \+                  \-                     \+            \-                  \-
  **Cai (2006)**                   \+                  \+                     \+            \+                  \+
  **Rossner (2006)**               \+                  \-                     \+            A                   \+
  **Zhang (2006)**                 \+                  \+                     \+            \+                  \+
  **Sangrajrang (2008)**           \+                  \-                     \+            \+                  \+
  **Synowiec (2008)**              \-                  \-                     \+            \-                  \+
  **Romanowicz-Makowska (2008)**   \-                  \-                     \+            \+                  \+
  **Ming-Shiean (2010)**           \+                  \-                     \+            \-                  \+
  **Sterpone (2010)**              B                   \+                     \+            \-                  \+
  **Roberts (2011)**               \+                  A,C                    \+            \+                  \+
  **Kim (2013)**                   \+                  \-                     \+            \-                  \+
  **Xie (2013)**                   \+                  \+                     \+            \+                  \+
  **Luo (2014)**                   \+                  \+                     \+            \+                  \+
  **McCullough (2014)**            \+                  D                      \+            \+                  \+
  **Rodrigues (2014)**             \+                  \+                     \+            \-                  \+
  **Smolarz (2014)**               \+                  \-                     \+            \-                  \+

^a^ Definitions: Year, year of publication; Source of control means clinic (or hospital) based or population based; population ethnicity means Caucasian, African-American and other ethnicity; Sample size means calculable sample size; Menopausal status means adjustment of menopausal status (post, pre or both) for final measure of association using methods such as adjustment in regression models, restriction, stratification etc; HWE (Hardy-Weinberg equilibrium) means calculated or reported HWE equilibrium.

^b^ A, Adjusted, but no detail presented; B, Source of controls: volunteers; C, Matched controls, but no detail presented; D, Only mentioned to ethnicity without adjustment.

###### Quality of Studies Assessing the Association Between XRCC1 Arg194Trp Polymorphism and Breast Cancer ^[a](#fn37888){ref-type="table-fn"},[b](#fn37889){ref-type="table-fn"}^

  Study (year)                    Source of Control   Population Ethnicity   Sample Size   Menopausal Status   HWE Reported
  ------------------------------- ------------------- ---------------------- ------------- ------------------- --------------
  **Duell (2001)**                \+                  \+                     \+            A                   \+
  **Kim (2002)**                  \+                  \-                     \+            \+                  \+
  **Han (2003)**                  \+                  B                      \+            C                   \+
  **Smith (2003)**                \+                  \+                     \+            \-                  \+
  **Smith (2003)**                \+                  \+                     \+            \-                  \+
  **Moullan (2003)**              \+                  \-                     \+            \-                  \+
  **Forsti (2004)**               \+                  \-                     \+            \-                  \+
  **Deligezer (2004)**            \-                  \-                     \+            \-                  \+
  **Chacko (2005)**               \+                  \-                     \+            \+                  \+
  **Shen (2005)**                 \+                  A                      \+            \+                  \+
  **Patel (2005)**                \+                  BD                     \+            \+                  \+
  **Pachkowski (2006)**           \+                  \+                     \+            \-                  \+
  **Thyagarajan (2006)**          \+                  \-                     \+            \-                  \+
  **Brewster (2006)**             \+                  \+                     \+            C                   \+
  **Zhang (2006)**                \+                  \+                     \+            \+                  \+
  **Silva (2007)**                \+                  \+                     \+            \+                  \+
  **Smith (2008)**                \+                  \+                     \+            \-                  \+
  **Sangrajrang (2008)**          \+                  \-                     \+            \+                  \+
  **Mitra (2008)**                E                   \+                     \+            D                   \+
  **Loizidou (2008)**             E                   \+                     \+            \-                  \+
  **Sobczuk (2009)**              \-                  \-                     \+            \+                  \+
  **Zipprich (2010)**             \+                  D                      \+            C                   \+
  **Ming-Shiean (2010)**          \+                  \-                     \+            \-                  \+
  **Sterpone (2010)**             E                   \+                     \+            \-                  \+
  **Liu (2011)**                  \+                  \+                     \+            \-                  \+
  **Przybylowska-Sygut (2013)**   \+                  \-                     \+            \-                  \+
  **Al Mutairi (2013)**           \+                  D                      \+            \-                  \+
  **Ding (2014)**                 \+                  \+                     \+            \-                  \+
  **McCullough (2014)**           \+                  B                      \+            \+                  \+
  **Ramadan (2014)**              \+                  \-                     \+            A                   \+
  **Smolarz (2014)**              \+                  \-                     \+            \-                  \+
  **Macias-Gomez (2015)**         \-                  \-                     \+            \-                  \+

^a^ Definitions:Year, year of publication; positive sign (+), mentioned in the articles; negative sign (-), not mentioned in the article; Source of control means clinic (or hospital) based or population based; Population ethnicity means Caucasian, African-American and other ethnicity; sample size means calculable sample size; Menopausal status means adjustment of menopausal status (post, pre or both) for final measure of association using methods such as adjustment inregression models, restriction, stratification etc; HWE (Hardy Weinberg equilibrium) means calculated or reported HWE equilibrium.

^b^ A, Calculated OR for different strata, but data not shown; B, Only mentioned to ethnicity without adjustment; C, Adjusted, but no detail presented; D, Matched controls, but no detail presented; E, Source of controls: volunteers.

###### Quality of Studies Assessing the Association Between Arg280His Polymorphism and Breast Cancer ^[a](#fn37890){ref-type="table-fn"},[b](#fn37891){ref-type="table-fn"}^

  Study (year)             Source of Control   Population Ethnicity   Sample Size   Menopausal Status   HWE Reported
  ------------------------ ------------------- ---------------------- ------------- ------------------- --------------
  **Moullan (2003)**       \+                  \-                     \+            \-                  \+
  **Chacko (2005)**        \+                  \-                     \+            \+                  \+
  **Metsola (2005)**       \+                  \+                     \+            A                   \+
  **Pachkowski (2006)**    \+                  \+                     \+            \-                  \+
  **Zhang (2006)**         \+                  \+                     \+            \+                  \+
  **Smith (2008)**         \+                  \+                     \+            \-                  \+
  **Loizidou (2008)**      B                   \+                     \+            \-                  \+
  **Sangrajrang (2008)**   \+                  \-                     \+            \+                  \+
  **Zipprich (2010)**      \+                  C                      \+            D                   \+
  **Liu (2011)**           \+                  \+                     \+            \-                  \+

^a^ Definitions: Year, year of publication; Source of control means clinic (or hospital) based or population based; Population ethnicity means Caucasian, African-American and other ethnicity; Sample size means calculable sample size; Menopausal status means adjustment of menopausal status (post, pre or both) for final measure of association using methods such as adjustment in regression models, restriction, stratification etc; HWE (Hardy Weinberg equilibrium) means calculated or reported HWE equilibrium.

^b^ A, Calculated OR for different strata, but data not shown; B, Source of controls: volunteers; C, Matched controls, but no detail presented; D, Adjusted, but no detail presented.

###### Quality of Studies Assessing the Association Between Arg399Gln Polymorphism and Breast Cancer ^[a](#fn37892){ref-type="table-fn"},[b](#fn37893){ref-type="table-fn"}^

  Study (year)                    Source of Control   Population Ethnicity   Sample Size   Menopausal Status   HWE Reported
  ------------------------------- ------------------- ---------------------- ------------- ------------------- --------------
  **Duell (2001)**                \+                  \+                     \+            A                   \+
  **Kim (2002)**                  \+                  \-                     \+            \+                  \+
  **Han (2003)**                  \+                  B                      \+            C                   \+
  **Shu (2003)**                  \+                  \+                     \+            \+                  \+
  **Smith (2003)**                \+                  \+                     \+            \-                  \+
  **Smith (2003)**                \+                  \+                     \+            \-                  \+
  **Moullan (2003)**              \+                  \-                     \+            \-                  \+
  **Deligezer (2004)**            \-                  \-                     \+            \-                  \+
  **Figueiredo (2004)**           \+                  B,C                    \+            \-                  \+
  **Forsti (2004)**               \+                  \-                     \+            \-                  \+
  **Huang (2004)**                \+                  \-                     \+            \-                  \-
  **Metsola (2005)**              \+                  \+                     \+            A                   \+
  **Chacko (2005)**               \+                  \-                     \+            \+                  \+
  **Dufloth (2005)**              D                   \-                     \+            \-                  \-
  **Patel (2005)**                \+                  BE                     \+            \+                  \+
  **Shen (2005)**                 \+                  A                      \+            \+                  \+
  **Brewster (2006)**             \+                  \+                     \+            C                   \+
  **Bu (2006)**                   \+                  B                      \+            \-                  \+
  **Pachkowski (2006)**           \+                  \+                     \+            \-                  \+
  **Thyagarajan (2006)**          \+                  \-                     \+            \-                  \+
  **Zhai (2006)**                 \+                  \+                     \+            \+                  \+
  **Zhang (2006)**                \+                  \+                     \+            \+                  \+
  **Costa (2007)**                \+                  \-                     \+            \-                  \+
  **Silva (2007)**                \+                  \+                     \+            \+                  \+
  **Ali (2008)**                  \+                  \-                     \+            \-                  \-
  **Kipikasova (2008)**           D                   \+                     \+            \-                  \+
  **Mitra (2008)**                D                   \+                     \+            E                   \+
  **Loizidou (2008)**             D                   \+                     \+            \-                  \+
  **Saadat (2008)**               \-                  \+                     \+            \+                  \+
  **Smith (2008)**                \+                  \+                     \+            \-                  \+
  **Sangrajrang (2008)**          \+                  \-                     \+            \+                  \+
  **Sobczuk (2009)**              \-                  \-                     \+            \+                  \+
  **Syamala (2009)**              \+                  \-                     \+            \-                  \-
  **Jelonek (2010)**              \+                  \+                     \+            \-                  \+
  **Jakubowska (2010)**           \+                  \-                     \+            \-                  \-
  **Ming-Shiean (2010)**          \+                  \-                     \+            \-                  \+
  **Sterpone (2010)**             D                   \+                     \+            \-                  \+
  **Santos (2010)**               D                   \-                     \+            \-                  \+
  **Romanowicz (2010)**           \-                  \-                     \+            \+                  \+
  **Zipprich (2010)**             \+                  E                      \+            C                   \+
  **Liu (2011)**                  \+                  \+                     \+            \-                  \+
  **Roberts (2011)**              \+                  C,E                    \+            \+                  \+
  **Hussien (2012)**              \+                  \-                     \+            \-                  \+
  **Al Mutairi (2013)**           \+                  E                      \+            \-                  \+
  **Sapkota (2013)**              \+                  \+                     \+            \-                  \+
  **Przybylowska-Sygut (2013)**   \+                  \-                     \+            \-                  \+
  **Ding (2014)**                 \+                  \+                     \+            \-                  \+
  **Luo (2014)**                  \+                  \+                     \+            \+                  \+
  **Ramadan**                     \+                  \-                     \+            A                   \+
  **Shadrina (2014)**             \+                  \+                     \+            \-                  \+
  **Macias-Gomez (2015)**         \-                  \-                     \+            \-                  \+

^a^ Year, year of publication; Source of control means clinic (or hospital) based or population based; Population ethnicity means Caucasian, African-American and other ethnicity; Sample size means calculable sample size; Menopausal status means adjustment of menopausal status (post, pre or both) for final measure of association using methods such as adjustment in regression models, restriction, stratification etc; HWE (Hardy Weinberg equilibrium) means calculated or reported HWE equilibrium.

^b^ A, Calculated OR for different strata, but data not shown; B, Only mentioned to ethnicity without adjustment; C, Adjusted, but no detail presented; D, Source of controls: volunteers; E, Matched controls, but no detail presented.

###### Characteristics of Literature Included in the Systematic Review Evaluating the Association Between XRCC1 Arg194Trp Polymorphism and Breast Cancer ^[a](#fn37894){ref-type="table-fn"}^

  First Author                 Date   Country        Ethnicity                                                                              Study Design       Control Source     Genotyping Methods                                                                                                        Analyzed Sample Size (Case Number)   Minor Allele Frequency (Case/Control)   Considered Confounders ^[b](#fn37895){ref-type="table-fn"}^
  ---------------------------- ------ -------------- -------------------------------------------------------------------------------------- ------------------ ------------------ ------------------------------------------------------------------------------------------------------------------------- ------------------------------------ --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Duell, E. J.**             2001   USA            African-Americans                                                                      population based   population based   multiplex PCR-RFLP and 59-exoncuclease (Taqman)                                                                           327 (161)                            (0.05/0.06)                             age
  **Duell, E. J.**             2001   USA            Whites                                                                                 population based   population based   multiplex PCR-RFLP and 59-exoncuclease (Taqman)                                                                           485 (251)                            (0.05/0.06)                             age
  **Kim, S. U.**               2002   Korea          NS                                                                                     hospital based     hospital based     PCR-RFLP                                                                                                                  410 (205)                            (0.34/0.34)                             breast feeding, family history of breast cancer and menopausal status at baseline
  **Han, J.**                  2003   USA            Caucasian, Southern European, Scandinavian, Asians, Hispanics, and African Americans   population based   population based   pyrosequencing, RFLP, and the 5 nuclease assay (TaqMan)                                                                   2367 (998)                           (0.05/0.06)                             age; menopausal status; postmenopausal hormone use; date of blood draw; time of blood draw; fasting status, body mass index at age 18 years, weight gain since age 18 years, age at menarche, age at menopause, parity/age at first birth, first-degree family history of breast cancer, history of benign breast disease, alcohol intake, during smoking, and duration of postmenopausal hormone use
  **Moullan, N.**              2003   France         NS                                                                                     hospital based     population based   TaqMan technology or variant specific restriction enzyme digestion                                                        566 (254)                            (0.07/0.06)                             age
  **Smith, T. R.**             2003   USA            Caucasian                                                                              hospital based     hospital based     PCR-RFLP                                                                                                                  512 (246)                            (0.07/0.04)                             age, family history, age at menarche, age at first live birth, and body mass index
  **Smith, T. R.**             2003   USA            Caucasian                                                                              hospital based     hospital based     PCR-RFLP                                                                                                                  463 (162)                            (0.07/0.06)                             age
  **Deligezer, U.**            2004   Turkey         NS                                                                                     NS                 NS                 multiplex PCR                                                                                                             284 (151)                            (0.03/0.05)                             \-
  **Forsti, A.**               2004   Finland        NS                                                                                     NS                 population based   PCR-RFLP                                                                                                                  521 (223)                            (0.03/0.02)                             \-
  **Chacko, P.**               2005   India          NS                                                                                     hospital based     hospital based     PCR-RFLP and DNA sequencing techniques                                                                                    246 (123)                            (0.21/0.12)                             age and menopausal status
  **Patel, A. V.**             2005   USA            white, African-American, Hispanic, Asian, other/unknown                                population based   population based   Taqman                                                                                                                    970 (485)                            NC                                      matched pairs, body mass index, age at menopause, age at menarche, alcohol intake, education, parity, age at first live birth, physical activity, history of breast cysts, family history of breast cancer in mother or sister, use of hormone replacement therapy, and smoking status
  **Shen, J.**                 2005   USA            White or non-White                                                                     population based   population based   fluorescence polarization method                                                                                          2177 (1067)                          NC                                      age at menarche, parity, lactation, months of lactation, age at first birth, number of miscarriages, history of fertility problems, body mass index at reference, body mass index at age 20, first-degree family history of breast cancer, history of benign breast disease, menopausal status, oral contraceptive use, hormone replacement use, race, education, religion, and marital status
  **Brewster, A. M.**          2006   USA            Mostly Caucasian                                                                       population based   population based   patented ﬂuorogenic method for nucleic acid analysis(Taqman or 5'nuclease assay) and PCR-RFLP                             615 (305)                            (0.06/0.06)                             family history
  **Pachkowski, B. F.**        2006   USA            African Americans                                                                      population based   Population based   the ABI 7700 sequence detection system or ''Taqman'' assay                                                                1456 (774)                           (0.07/0.07)                             offsets and age
  **Pachkowski, B. F.**        2006   USA            Whites                                                                                 population based   population based   the ABI 7700 sequence detection system or ''Taqman'' assay                                                                2407 (1281)                          (0.06/0.07)                             offsets and age
  **Thyagarajan, B.**          2006   USA            NS                                                                                     population based   population based   PCR-RFLP, PCR-INVADER, or Sequenom                                                                                        626 (309)                            (0.07/0.06)                             age, family history of breast cancer among ﬁrst degree relatives, physical activity, body mass index
  **Zhang, Y.**                2006   USA            Caucasian                                                                              Population based   population based   TaqMan                                                                                                                    2833 (1580)                          (0.06/0.07)                             age and study site
  **Silva, S. N.**             2007   Portugal       Caucasian Portuguese                                                                   hospital based     hospital based     PCR-RFLP                                                                                                                  693 (240)                            (0.08/0.06)                             age at diagnosis; alcohol consumption and smoking habits
  **Loizidou, M. A.**          2008   Greece         Greek Cypriots                                                                         population based   volunteers         PCR-RFLP                                                                                                                  2261 (1097)                          ( 0.08/0.08)                            \-
  **Mitra, A. K.**             2008   India          Caucasians of Indo-European                                                            hospital based     volunteers         PCR-RFLP                                                                                                                  376 (151)                            (0.06/0.14)                             \-
  **Sangrajrang, S.**          2008   Thailand       NS                                                                                     hospital based     hospital based     rapid capillary PCR followed by melting curve analysis using ﬂuorescence labeled hybridization probes in a light cycler   931 (506)                            (0.30/0.31)                             age, body mass index, age at menarche, family history of breast cancer, reproduction parameters, use of contraceptives, menopausal status, hazardous lifestyle, and education
  **Smith, T. R.**             2008   USA            Caucasian                                                                              hospital based     Hospital based     mass ARRAY system                                                                                                         735 (324)                            (0.07/0.05)                             age, family history of breast cancer, smoking history, age at menarche, age at ﬁrst live birth and body mass index
  **Smith, T. R.**             2008   USA            African-American                                                                       hospital based     hospital based     mass ARRAY system                                                                                                         128(53)                              (0.06/0.06)                             age, family history of breast cancer, smoking history, age at menarche, age at ﬁrst live birth and body mass index
  **Sobczuk, A.**              2009   Poland         NS                                                                                     NS                 NS                 PCR-RFLP                                                                                                                  256 (150)                            (0.53/0.57)                             \-
  **Ming-Shiean, H.**          2010   Taiwan         NS                                                                                     hospital based     hospital based     real-time PCR with the TaqMan assay system                                                                                934 (401)                            (0.32/0.28)                             age, age at ﬁrst full-term pregnancy, cigarette smoking, body mass index, and family history
  **Sterpone, S.**             2010   Italy          Caucasian                                                                              hospital based     volunteers         PCR-RFLP                                                                                                                  74 (43)                              (0.08/0.04)                             \-
  **Zipprich, J.**             2010   USA            NS                                                                                     population based   population based   fluorescence polarization method                                                                                          559 (254)                            NC                                      menopause and age and age at menarche
  **Liu, L.**                  2011   China          Han Chinese                                                                            hospital based     population based   PCR-RFLP                                                                                                                  1999 (995)                           (0.30/0.27)                             age
  **Al Mutairi, F. M.**        2013   Saudi Arabia   NS                                                                                     hospital based     hospital based     TaqMan SNP genotype analysis technique                                                                                    200(100)                             (0.08/0.02)                             \-
  **Przybylowska-Sygut, K.**   2013   Poland         NS                                                                                     hospital based     population based   PCR-RFLP                                                                                                                  390 (185)                            (0.14/0.08)                             \-
  **Ding, P.**                 2014   China          Han Chinese                                                                            hospital based     hospital based     polymerase chain reaction-ligase detection reaction (PCR-LDR)                                                             1239 (606)                           (0.32/0.32)                             age
  **McCullough, L. E.**        2014   USA            White and black                                                                        population based   population based   fluorescence polarization (FP) method                                                                                     1166 (598)                           NC                                      age
  **Ramadan, R. A.**           2014   Egypt          NS                                                                                     hospital based     hospital based     PCR-RFLP                                                                                                                  175(100)                             (0.40/0.20)                             age, body mass index , parity, menopausal status, age at menarche, family history of breast cancer, smoking, or physical activity
  **Smolarz, B.**              2014   Poland         NS                                                                                     hospital based     hospital based     PCR-RFLP                                                                                                                  140 (70)                             (0.49/0.50)                             \-
  **Macias-Gomez, N. M.**      2015   Mexico         NS                                                                                     hospital based     NS                 PCR-RFLP                                                                                                                  697 (345)                            (0.16/0.15)                             \-

^a^ Definitions: Date, year of publication; NS, not state; NC, not calculable; USA, United State of America.

^b^ Confounders in multivariate analysis.

###### Characteristics of Literature Included in the Systematic Review Evaluating the Association Between XRCC1 Arg280His Polymorphism and Breast Cancer ^[a](#fn37898){ref-type="table-fn"}^

  First Author            Date   Country    Ethnicity           Study Design       Control Source     Genotyping Methods                                                                                                        Analyzed Sample Size (Case Number)   Minor Allele Frequency (Case/Control)   Considered Confounders ^[b](#fn37899){ref-type="table-fn"}^
  ----------------------- ------ ---------- ------------------- ------------------ ------------------ ------------------------------------------------------------------------------------------------------------------------- ------------------------------------ --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Moullan, N.**         2003   France     NS                  hospital based     population based   TaqMan technology or variant specific restriction enzyme digestion                                                        566 (254)                            (0.08/0.04)                             age
  **Chacko, P.**          2005   India      NS                  hospital based     hospital based     PCR-RFLP and DNA sequencing techniques                                                                                    246 (123)                            (0.11/0.14)                             age and menopausal status
  **Metsola, K.**         2005   Finland    Caucasian           hospital based     population based   PCR-RFLP                                                                                                                  959 (480)                            (0.08/0.07)                             age, age at menarche, age at first full term pregnancy, number of pregnancies, history of benign breast disease, first degree family history of breast cancer, waist-to-hip ratio, smoking and use of alcohol
  **Pachkowski, B. F.**   2006   USA        African Americans   population based   population based   the ABI 7700 sequence detection system or ''Taqman'' assay                                                                1446 (765)                           (0.04/0.03)                             offsets and age
  **Pachkowski, B. F.**   2006   USA        Whites              population based   population based   the ABI 7700 sequence detection system or ''Taqman'' assay                                                                2400 (1271)                          (0.05/0.04)                             offsets and age
  **Zhang, Y.**           2006   USA        Caucasian           population based   population based   TaqMan                                                                                                                    2802 (1564)                          (0.05/0.04)                             age and study site
  **Loizidou, M. A.**     2008   Greece     Greek Cypriots      population based   volunteers         PCR-RFLP                                                                                                                  2277 (1109)                          ( 0.08/0.09)                            \-
  **Sangrajrang, S.**     2008   Thailand   NS                  hospital based     hospital based     rapid capillary PCR followed by melting curve analysis using ﬂuorescence labeled hybridization probes in a light cycler   932 (507)                            (0.08/0.07)                             age, body mass index, age at menarche, family history of breast cancer, reproduction parameters, use of contraceptives, menopausal status, hazardous lifestyle, and education
  **Smith, T. R.**        2008   USA        Caucasian           hospital based     hospital based     mass ARRAY system                                                                                                         732 (324)                            (0.04/0.05)                             age, family history of breast cancer, smoking history, age at menarche, age at ﬁrst live birth and body mass index
  **Smith, T. R.**        2008   USA        African-American    hospital based     hospital based     mass ARRAY system                                                                                                         128 (53)                             (0.03/0.04)                             age, family history of breast cancer, smoking history, age at menarche, age at ﬁrst live birth and body mass index
  **Zipprich, J.**        2010   USA        NS                  population based   population based   fluorescence polarization method                                                                                          599 (271)                            NC                                      menopause and age and age at menarche
  **Liu, L.**             2011   China      Han Chinese         hospital based     population based   PCR-RFLP                                                                                                                  1999 (995)                           (0.09/0.10)                             age

^a^ Definitions: Date, year of publication; NS, not state; NC, not calculable; USA, United State of America.

^b^ Confounders in multivariate analysis.

###### Characteristics of Literature Included in the Systematic Review Evaluating the Association Between XRCC1 Arg399Gln Polymorphism and Breast Cancer ^[a](#fn37900){ref-type="table-fn"}^

  First Author                 Date   Country        Ethnicity                                                                              Study Design       Control Source                          Genotyping Methods                                                                                                          Analyzed Sample Size (Case Number)   Minor Allele Frequency (Case/Control)   Considered Confounders ^[b](#fn37901){ref-type="table-fn"}^
  ---------------------------- ------ -------------- -------------------------------------------------------------------------------------- ------------------ --------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------------------------ --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Duell, E. J.**             2001   USA            African-Americans                                                                      population based   population based                        multiplex PCR-RFLP and 59-exoncuclease (Taqman)                                                                             519(253)                             (0.19/0.14)                             age
  **Duell, E. J.**             2001   USA            Whites                                                                                 population based   population based                        multiplex PCR-RFLP and 59-exoncuclease (Taqman)                                                                             767(386)                             (0.35/0.36)                             AGE
  **Kim, S. U.**               2002   Korea          NS                                                                                     hospital based     hospital based                          PCR-RFLP                                                                                                                    410(205)                             (0.35/0.31)                             breast feeding, family history of breast cancer and menopausal status at baseline
  **Han, J.**                  2003   USA            Caucasian, Southern European, Scandinavian, Asians, Hispanics, and African Americans   population based   population based                        pyrosequencing, RFLP, and the 5 nuclease assay (TaqMan)                                                                     2323(986)                            (0.37/0.36)                             age; menopausal status; postmenopausal hormone use; date of blood draw; time of blood draw; fasting status, body mass index at age 18 years, weight gain since age 18 years, age at menarche, age at menopause, parity/age at first birth, first-degree family history of breast cancer, history of benign breast disease, alcohol intake, during smoking, and duration of postmenopausal hormone use
  **Moullan, N.**              2003   France         NS                                                                                     hospital based     population based                        TaqMan technology or variant specific restriction enzyme digestion                                                          566(254)                             (0.34/0.35)                             age
  **Shu, X. O.**               2003   China          Han Chinese                                                                            population based   population based                        PCR-based RFLP                                                                                                              2270(1088)                           (0.28/0.27)                             age, education, family history of breast cancer, menopausal status, age at menarche, age at menopause, body mass index, waist: hip ratio, and physical activity
  **Smith, T. R.**             2003   USA            Caucasian                                                                              hospital based     hospital based                          PCR-RFLP                                                                                                                    518(251)                             (0.36/0.33)                             age, family history, age at menarche, age at first live birth, and body mass index
  **Smith, T. R.**             2003   USA            Caucasian                                                                              hospital based     hospital based                          PCR-RFLP                                                                                                                    462(162)                             (0.34/0.35)                             age
  **Deligezer, U.**            2004   Turkey         NS                                                                                     NS                 NS                                      multiplex PCR                                                                                                               284(151)                             (0.39/0.37)                             \-
  **Figueiredo, J. C.**        2004   Canada         Caucasian-Native or Caucasian-Asian or Caucasian-Black                                 population based   population based                        matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry                                    804(402)                             (0.35/0.37)                             ethnicity, age, and family history of breast cancer
  **Forsti, A.**               2004   Finland        NS                                                                                     NS                 population based                        PCR-RFLP                                                                                                                    521(223)                             (0.32/0.32)                             \-
  **Huang, C. S.**             2004   Taiwan         NS                                                                                     hospital based     hospital based                          PCR-RFLP                                                                                                                    368(136)                             (0.27/0.23)                             \-
  **Chacko, P.**               2005   India          NS                                                                                     hospital based     hospital based                          PCR-RFLP and DNA sequencing techniques                                                                                      246 (123)                            (0.34/0.21)                             age and menopausal status
  **Dufloth, R. M.**           2005   Brazil         NS                                                                                     hospital based     volunteers (among hospital personnel)   PCR-RFLP                                                                                                                    205(86)                              (0.27/0.29)                             \-
  **Metsola, K.**              2005   Finland        Caucasian                                                                              hospital based     population based                        PCR-RFLP                                                                                                                    957(479)                             (0.30/0.27)                             age, age at menarche, age at first full term pregnancy, number of pregnancies, history of benign breast disease, first degree family history of breast cancer, waist-to-hip ratio, smoking and use of alcohol.
  **Patel, A. V.**             2005   USA            White, African-American, Hispanic, Asian, other/unknown                                population based   population based                        Taqman                                                                                                                      904(452)                             (0.35/0.34)                             matched pairs, body mass index, age at menopause, age at menarche, alcohol intake, education, parity, age at first live birth, physical activity, history of breast cysts, family history of breast cancer in mother or sister, use of hormone replacement therapy, and smoking status
  **Shen, J.**                 2005   USA            White or non-White                                                                     population based   population based                        fluorescence polarization method                                                                                            2177(1067)                           ( 0.36/0.35)                            age at menarche, parity, lactation, months of lactation, age at first birth, number of miscarriages, history of fertility problems, body mass index at reference, body mass index at age 20, first-degree family history of breast cancer, history of benign breast disease, menopausal status, oral contraceptive use, hormone replacement use, race, education, religion, and marital status
  **Brewster, A. M.**          2006   USA            mostly Caucasian                                                                       population based   population based                        patented ﬂuorogenic method for nucleic acid analysis(Taqman or 5'nuclease assay) and PCR-RFLP                               615(305)                             (0.38/0.37)                             family history
  **Bu, D.**                   2006   USA            Caucasian, Black, Hispanic, Ashkenazi Jewish                                           hospital based     hospital based                          multiplex primer extension PCR                                                                                              285(190)                             (0.34/0.33)                             \-
  **Pachkowski, B. F.**        2006   USA            African Americans                                                                      population based   population based                        the ABI 7700 Sequence Detection System or ''Taqman'' assay                                                                  1437(761)                            (0.16/0.14)                             offsets and age
  **Pachkowski, B. F.**        2006   USA            Whites                                                                                 population based   population based                        the ABI 7700 sequence detection system or ''Taqman'' assay                                                                  2366(1244)                           (0.36/0.35)                             offsets and age
  **Thyagarajan, B.**          2006   USA            NS                                                                                     population based   population based                        PCR-RFLP, PCR-invader, or Sequenom                                                                                          515(193)                             (0.50/0.36)                             age, family history of breast cancer among ﬁrst degree relatives, physical activity, body mass index
  **Zhai, X.**                 2006   China          Han Chinese                                                                            hospital based     population based                        PCR-RFLP                                                                                                                    941(302)                             ( 0.25/0.26)                            age, age at menarche and menopausal
                                                                                                                                                                                                                                                                                                                                                                                                                status
  **Zhang, Y.**                2006   USA            Caucasian                                                                              population based   population based                        TaqMan                                                                                                                      5626(3039)                           (0.36/0.36)                             age and study site
  **Zhang, Y.**                2006   Poland         Caucasian                                                                              population based   population based                        TaqMan                                                                                                                      4275(1985)                           (0.37/0.35)                             age and study site
  **Costa, S.**                2007   Portugal       NS                                                                                     hospital based     population based                        PCR-RFLP                                                                                                                    917(256)                             (0.34/0.39)                             age
  **Silva, S. N.**             2007   Portugal       Caucasian Portuguese                                                                   hospital based     hospital based                          PCR-RFLP                                                                                                                    697(241)                             (0.31/0.34)                             age at diagnosis; alcohol consumption and smoking habits
  **Ali, M. F.**               2008   USA            NS                                                                                     hospital based     hospital based                          PCR-RFLP                                                                                                                    88(40)                               (0.52/0.53)                             \-
  **Kipikasova, L.**           2008   Slovakia       Caucasian                                                                              hospital based     volunteers                              PCR with confronting two pair primers (PCR-CTPP)                                                                            227(114)                             (0.35/0.34)                             \-
  **Loizidou, M. A.**          2008   Greece         Greek Cypriots                                                                         population based   volunteers                              PCR-RFLP                                                                                                                    2283(1107)                           ( 0.32/0.33)                            \-
  **Mitra, A. K.**             2008   India          Caucasians of Indo-Europeans                                                           hospital based     volunteers                              PCR-RFLP                                                                                                                    375(150)                             (0.39/0.53)                             \-
  **Saadat, M.**               2008   Iran           Persian Muslims                                                                        hospital based     NS                                      PCR-RFLP                                                                                                                    373(186)                             (0.36/0.32)                             family history of breast cancer in ﬁrst-degree relatives and cigarette smoking
  **Sangrajrang, S.**          2008   Thailand       NS                                                                                     hospital based     hospital based                          rapid capillary PCR followed by melting curve analysis using ﬂuorescence labeled hybridization probes in a Light Cycler     931(507)                             (0.27/0.23)                             age, body mass index, age at menarche, family history of breast cancer, reproduction parameters, use of contraceptives, menopausal status, hazardous lifestyle, and education
  **Smith, T. R.**             2008   USA            Caucasian                                                                              hospital based     hospital based                          mass ARRAY system                                                                                                           718(312)                             (0.34/0.33)                             age, family history of breast cancer, smoking history, age at menarche, age at ﬁrst live birth and body mass index
  **Smith, T. R.**             2008   USA            African-American                                                                       hospital based     hospital based                          mass ARRAY system                                                                                                           126(52)                              (0.14/0.11)                             age, family history of breast cancer, smoking history, age at menarche, age at ﬁrst live birth and body mass index
  **Sobczuk, A.**              2009   Poland         NS                                                                                     NS                 NS                                      PCR-RFLP                                                                                                                    256(150)                             (0.55/0.57)                             \-
  **Syamala, V. S.**           2009   India          NS                                                                                     hospital based     hospital based                          PCR-RFLP                                                                                                                    726(359)                             (0.37/0.30)                             age
  **Jakubowska, A.**           2010   Poland         NS                                                                                     NS                 NS                                      PCR-based fragment analyses using the CEQTM 8000 Genetic DNA Analysis System and/or ethidium bromide-stained agarose gels   607(317)                             (0.35/0.39)                             index, year of birth and BRCA1 mutation
  **Jelonek, K.**              2010   Poland         Caucasian                                                                              hospital based     hospital based                          PCR-RFLP                                                                                                                    645(94)                              (0.35/0.37)                             \-
  **Ming-Shiean, H.**          2010   Taiwan         NS                                                                                     hospital based     hospital based                          real-time PCR with the TaqMan assay system                                                                                  926(395)                             (0.31/0.29)                             age, age at ﬁrst full-term pregnancy, cigarette smoking, body mass index, and family history
  **Romanowicz, H.**           2010   Poland         NS                                                                                     hospital based     NS                                      PCR-RFLP                                                                                                                    440(220)                             (0.44/0.34)                             \-
  **Santos, R. A.**            2010   Brazil         NS                                                                                     NS                 volunteers                              PCR-RFLP                                                                                                                    150(65)                              (0.33/0.40)                             \-
  **Sterpone, S.**             2010   Italy          Caucasian                                                                              hospital based     volunteers                              PCR-RFLP                                                                                                                    74(43)                               (0.53/0.32)                             \-
  **Zipprich, J.**             2010   USA            NS                                                                                     population based   population based                        fluorescence polarization method                                                                                            555(254)                             (0.30/0.34)                             menopause and age and age at menarche
  **Liu, L.**                  2011   China          Han Chinese                                                                            hospital based     population based                        PCR-RFLP                                                                                                                    1999(995)                            (0.26/0.28)                             age
  **Roberts, M. R.**           2011   USA            NS                                                                                     hospital based     population based                        matrix-assisted laser desorption ionization time-of-ﬂightmass spectrometry                                                  2752(982)                            (0.34/0.32)                             age, education, race, smoking status, age at ﬁrst birth, family history of breast cancer, history of benign breast disease, age at menarche and hormone therapy use
  **Hussien, Y. M.**           2012   Egypt          NS                                                                                     hospital based     hospital based                          PCR-CTPP method                                                                                                             200(100)                             (0.37/0.30)                             age
  **Al Mutairi, F. M.**        2013   Saudi Arabia   NS                                                                                     hospital based     hospital based                          TaqMan SNP genotype analysis technique                                                                                      200(100)                             (0.26/0.25)                             \-
  **Przybylowska-Sygut, K.**   2013   Poland         NS                                                                                     hospital based     population based                        PCR-RFLP                                                                                                                    390(185)                             (0.36/0.37)                             \-
  **Sapkota, Y.**              2013   Canada         Caucasian                                                                              population based   population based                        sequenom iPLEX Gold platform                                                                                                7225(2720)                           NC                                      body mass index
  **Ding, p.**                 2014   China          Han Chinese                                                                            hospital based     hospital based                          polymerase chain reaction-ligase detection reaction (PCR-LDR)                                                               1239(606)                            (0.30/0.25)                             Age
  **Luo, H.**                  2014   China          Han Chinese                                                                            hospital based     hospital based                          PCR-CTPP                                                                                                                    439(194)                             (0.34/0.25)                             age, age at menarche, pregnancy, menopausal status, body mass index, and family history of cancer
  **McCullough, L. E.**        2014   USA            White and Black                                                                        population based   population based                        fluorescence polarization (FP) method                                                                                       1163(597)                            NC                                      age
  **Ramadan, R. A.**           2014   Egypt          NS                                                                                     hospital based     hospital based                          PCR-RFLP                                                                                                                    175(100)                             (0.44/0.29)                             age, body mass index, parity, menopausal status, age at menarche, family history of breast cancer,
                                                                                                                                                                                                                                                                                                                                                                                                                smoking, or physical activity
  **Shadrina, A. S**           2014   Russia         Caucasian                                                                              NS                 hospital based                          real-time PCR allelic discrimination with TaqMan probes                                                                     1222(658)                            (0.36/0.31)                             age
  **Macias-Gomez, N. M.**      2015   Mexico         NS                                                                                     hospital based     NS                                      PCR-RFLP                                                                                                                    686(345)                             (0.29/0.23)                             \-

^a^ Definitions: Date, year of publication; NS, not state; NC, not calculable; USA, United State of America.

^b^ Confounders in multivariate analysis.

###### Characteristics of Literature Included in the Systematic Review Evaluating the Association Between OGG1 Ser326Cys Polymorphism and Breast Cancer ^a^

  First Author                  Date   Country    Ethnicity         Study Design       Control Source     Genotyping Methods                                                                                                        Analyzed Sample Size (Case Number)   Minor Allele Frequency (Case/Control)   Considered Confounders ^[b](#fn37905){ref-type="table-fn"}^
  ----------------------------- ------ ---------- ----------------- ------------------ ------------------ ------------------------------------------------------------------------------------------------------------------------- ------------------------------------ --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Choi, J. Y.**               2003   Korea      Korean            hospital based     hospital based     PCR-RFLP                                                                                                                  549 (265)                            (0.56/0.55)                             age, body mass index, family history of breast cancer, and parity factor
  **Choi, J. Y.**               2003   Japan      Japanese          hospital based     hospital based     PCR-CTPP                                                                                                                  389 (201)                            (0.48/0.42)                             age, body mass index , family history of breast cancer, and parity factor
  **Vogel, U.**                 2003   Denmark    NS                population based   population based   real-time PCR                                                                                                             869 (425)                            (0.22/0.24)                             \-
  **Huang, C. S.**              2004   Taiwan     NS                hospital based     hospital based     PCR-RFLP                                                                                                                  368 (136)                            (0.58/0.60)                             \-
  **Cai, Q.**                   2006   China      Han Chinese       population based   population based   fluorogenic 5´ nuclease assay with primers                                                                                2269 (1102)                          (0.58/0.58)                             AGE, education level, menopausal status, and age at first live birth
  **Rossner, P., Jr.**          2006   USA        NS                population based   population based   template-directed dye-terminator incorporation assay with fluorescence polarization detection                             2134 (1041)                          (0.22/0.22)                             AGE and simultaneously adjusted for three SNPs
  **Zhang, Y.**                 2006   USA        Caucasian         population based   population based   TaqMan                                                                                                                    2815 (1571)                          (0.21/0.21)                             age and study site
  **Romanowicz-Makowska, H.**   2008   Poland     NS                NS                 NS                 PCR-RFLP                                                                                                                  206 (100)                            (0.51/0.57)                             \-
  **Sangrajrang, S.**           2008   Thailand   NS                hospital based     hospital based     rapid capillary PCR followed by melting curve analysis using ﬂuorescence labeled hybridization probes in a Light Cycler   930 (506)                            (0.55/0.50)                             age, body mass index, age at menarche, family history of breast cancer, reproduction parameters, use of contraceptives, menopausal status, hazardous lifestyle, and education
  **Synowiec, E.**              2008   Poland     NS                hospital based     NS                 PCR-RFLP                                                                                                                  89 (41)                              (0.52/0.68)                             age
  **Ming-Shiean, H.**           2010   Taiwan     NS                hospital based     hospital based     real-time PCR with the TaqMan assay system                                                                                934 (401)                            (0.63/0.62)                             age, age at ﬁrst full-term pregnancy, cigarette smoking, body mass index, and family history
  **Sterpone, S.**              2010   Italy      Caucasian         hospital based     volunteers         PCR-RFLP                                                                                                                  74 (43)                              (0.31/0.29)                             \-
  **Roberts, M. R.**            2011   USA        NS                hospital based     population based   matrix-assisted laser desorption ionization time-of-ﬂightmass spectrometry                                                2941 (1054)                          (0.22/0.22)                             age, education, race, smoking status, age at ﬁrst birth, family history of breast cancer, history of benign breast disease, age at menarche and hormone therapy use
  **Kim, K. Y.**                2013   Korea      NS                hospital based     population based   Illumina GoldenGate™method                                                                                                707 (346)                            (0.47/0.49)                             age, family history and body mass index
  **Xie, H.**                   2013   China      Han Chinese       hospital based     hospital based     PCR and high-resolution melting and sequencing                                                                            1407 (630)                           (0.60/0.56)                             \-
  **Luo, H.**                   2014   China      Han Chinese       hospital based     hospital based     PCR-CTPP                                                                                                                  439 (194)                            (0.55/0.59)                             age, age at menarche, pregnancy, menopausal status, body mass index, and family history of cancer
  **McCullough, L. E.**         2014   USA        White and black   population based   population based   fluorescence polarization (FP) method                                                                                     1135(580)                            NC                                      age
  **Rodrigues, P.**             2014   Spain      Caucasian         hospital based     hospital based     SNPlex technology (based on oligation assay/polymerase chain reaction and capillary electrophoresis)                      2123(711)                            (-/0.21)                                age
  **Smolarz, B.**               2014   Poland     NS                hospital based     hospital based     PCR-RFLP                                                                                                                  140 (70)                             (0.49/0.50)                             \-

^b^ Confounders in multivariate analysis.
